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 Type 1 diabetes mellitus (T1DM) is an endocrine disorder that continues to afflict a growing 
proportion of the U.S. population.  Characterized by an autoimmune attack on the pancreatic [beta] cells 
that leads to their destruction, T1DM develops from absolute insulin deficiency resulting in chronic 
hyperglycemia. Although the disease requires lifelong insulin therapy and confers enhanced risk for 
long-term complications, the mechanism of [beta] cell death remains unclear. Fas receptor signaling is 
critical among cells of hematopoietic origin for its role in immune homeostasis and mediation of target 
cell death. Fas receptor-ligand interactions might also have a role in [beta] cell death leading to the 
development of T1DM; pro-inflammatory cytokines released from islet leukocytes can induce Fas 
receptor to the [beta] cell surface, and systemic loss-of-function mutations in Fas receptor and Fas 
ligand (FasL) abrogate disease in spontaneous diabetes-prone mice. However, systemic deficiency in Fas 
and FasL causes an alteration in the T cell repertoire that prevents diabetes, and thus cannot be 
attributed to absence of Fas [beta] cell signaling. Moreover, the use of distinct Fas mutations and 
transgenic models that produce dissimilar mechanisms of [beta] cell death leads to conflicting results 
reported in the scientific literature. Recent evidence using transgenic mouse models of diabetes has 
indicated a role for Fas in the insulitic phase but not the effector phase of [beta] cell death, while other 
studies have suggested that alteration of the T cell repertoire by Fas signaling is a causal factor in the 
autoimmune [beta] cell attack. Furthermore, ectopically-expressed FasL is a potential therapeutic tool 
for protection of islet transplants by its known ability to provide immune privilege in some tissues. This 
literature review collectively presents the diverse roles for Fas signaling in [beta] cell death and provides 
insight into why conflicting conclusions regarding Fas signaling currently exist. Thus, the goal of this 
literature review is to enable investigators interested in Fas-mediated signaling in the pancreatic [beta] 
cell to choose an appropriate model system for study design that ideally will translate to therapeutic 
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I. Characterization of Diabetes Mellitus 
 Diabetes mellitus is the umbrella term for the most common endocrine disorder affecting 
people in the United States. The rise in prevalence of this disease is accompanied by numerous studies 
devoted to understanding the molecular mechanism of action with the hope of generating novel 
therapeutic interventions. A much larger proportion of people now know at least one individual affected 
by diabetes and are dedicated to increasing awareness in an effort to gain funding for diabetes research.  
To appreciate the implications of living with diabetes and the critical need for effective therapies, it is 
important to understand the clinical characterization and pathogenesis of the disease. 
 Two major forms of diabetes exist: These are Type 1 (T1DM) and Type 2 (T2DM) and they share 
a common phenotype of overall losses in functional β-cell mass leading to hyperglycemia. Diminution of 
the pancreatic β-cell mass results in insulin deficiency. Insulin is a hormone secreted by β-cells of the 
pancreatic islet of Langerhans, and is critical to blood glucose homeostasis via its ability to promote 
cellular glucose entry and exit from the circulation. Insulin secretion is controlled by a number of 
different fuel substrates, with glucose providing the biggest overall effect. Glucose-stimulated insulin 
secretion (GSIS) is directed by a complex interaction of multiple metabolic pathways that begins with β-
cell glucose entry and metabolism, and concludes with exocytosis of insulin-containing granules [1]. Loss 
of endogenous insulin signaling leads to alterations in fuel metabolism in a variety of tissues, and 
drastically impacts blood glucose homeostasis; the clinical manifestation is development of diabetes 
mellitus.  
 T2DM is the most prevalent form of diabetes, accounting for over 90% of total cases [2]. 





increase in young adults and adolescents. Development of the disorder is initiated with insulin 
resistance, whereby a decrease in insulin-mediated glucose uptake causes the pancreatic β-cell to 
respond by expanding its mass and increasing insulin secretion. However, once the β-cell can no longer 
expand or secrete sufficient amounts of insulin to match the rising insulin demands, occurrence of β-cell 
deficiency leads to impaired glucose tolerance and overt T2DM [3]. A number of factors are associated 
with increased risk for development of T2DM, and include an individual’s genetic background as well as 
environmental factors. For example, visceral fat accumulation has progressively increased among the US 
population in parallel with T2DM incidence. Although insulin resistance is the initial step in development 
of T2DM, only about one-third of obese insulin-resistant individuals progress to overt T2DM; only when 
the β-cell can no longer meet the body’s insulin demands do chronic hyperglycemia and diabetes 
develop.  
Gestational diabetes mellitus (GDM) is a form of diabetes that is significantly less prevalent than 
either T1DM or T2DM, affecting approximately 7% of pregnant women, but whose pathogenesis is 
similar to T2DM. GDM is most commonly diagnosed in the third trimester of gestation and can be 
treated with dietary intervention and exercise, although insulin therapy may be required for more 
severe cases. Although the disorder often resolves at birth, women treated for GDM are at a 
significantly increased risk for development of T2DM, and to a much lesser extent T1DM. Maternal GDM 
increases the offspring risk for adverse outcomes, most notably macrosomia [4]; intrauterine exposure 
to hyperglycemia has also been suggested to create metabolic memory that results in T2DM 
development later in life. Indeed, children born to mothers with GDM have a significantly enhanced risk 
for development of T2DM relative to children born to mothers who do not carry the disorder. 
T1DM is less prevalent than T2DM, yet currently affects approximately 900,000 people in the 
United States and is increasing at an alarming rate. Over 75% of these cases are onset at the age of 18 or 





individual’s immune system loses the ability to differentiate foreign microorganisms from self [5];  this 
results in immune dysregulation and expansion of autoreactive CD4+ and CD8+ T cells, as well as B 
lymphocytes and other cells of hematopoietic origin. The disorder is characterized by complete insulin 
deficiency secondary to autoimmune-mediated β-cell death, which occurs via a two-step process (Figure 
1). The first phase is known as insulitis, in which dendritic cells, macrophages, and lymphocytes (most 
abundantly CD8+ T lymphocytes), infiltrate the islet of Langerhans and cause inflammation upon release 
of pro-inflammatory cytokines. The islet of Langerhans contains multiple cell types: α, β, δ, ε, and PP 
cells, which exhibit endocrine function by their secretion of hormones directly into the bloodstream. 
Interestingly, however, T lymphocytes selectively target β-cells for death, leaving all other cell types 
residing within the islet free from the cytotoxic effect of these autoreactive cells.  The second and final 
effector phase of β-cell death is characterized by immune cell-mediated β-cell destruction through 
signaling mechanisms that are still unclear [6-8]. Progression of β-cell death is variable in duration, and 
clinical symptoms generally begin appearing after the loss of approximately 70-80% of β-cells [9]. Typical 
Figure 1. Schematic that diagrams progression of the islet β-cell to autoimmune-mediated death, 





signs of chronic hyperglycemia most commonly include polyphagia, polyuria, polydipsia, weight loss, and 
lethargy [10].  
After diagnosis of T1DM, treatment involves achieving a critical balance between insulin 
administration and food intake; the ultimate goal is to minimize fluctuations in self-monitored blood 
glucose levels, that when uncontrolled, enhance the risk for long-term complications. Insulin was 
discovered as the secreted pancreatic factor required to cure the disease symptoms [11] and indeed, 
insulin administration is still the only therapy available to treat Type 1 diabetes. For a number of years, 
subcutaneous injection multiple times daily was the only method of insulin administration. However, 
alternative routes of insulin administration have recently become available and provide the capability 
for tighter regulation of blood glucose levels, in addition to other factors. For example, the insulin pump 
allows for a constant basal insulin drip and is connected subcutaneously, so lessens the invasiveness of 
the treatment conferred by insulin injection. Furthermore, the pump may offer a way to maintain 
glycosylated hemoglobin (HbA1c) in a narrower range; HbA1c is a good measure of long-term average 
blood glucose levels. Importantly, the ability to maintain blood glucose levels near the normal range (70-
100 mg/dL) significantly lessens the risk for long-term complications [12]. Individuals with poorly 
controlled diabetes mellitus are at an enhanced risk for a plethora of long-term complications, including 
nephropathy, neuropathy, retinopathy, amputation, heart disease, and earlier than average mortality 
rates [13].  
 
II. Predisposing Factors that Affect Risk for T1DM 
 Some genes have a significant association with T1DM, and can have a role in either protection or 
enhanced vulnerability for the disorder. The human leukocyte antigen (HLA) is a region on chromosome 
6p21 that is also known as insulin-dependent diabetes mellitus locus (IDDMI). Susceptibility loci found 





associated gene, although more than 30 non-HLA regions have also been shown to affect risk for the 
disease [14]. HLA genes can also be used as markers of risk for T1DM, in combination with the presence 
of autoantibodies. This genetic link associated with vulnerability for T1DM is exemplified by family 
members of a Type 1 diabetic who themselves are also at enhanced risk for diabetes [15]. 
External precipitating events are just as noteworthy as genetic background in regards to 
triggering an autoimmune response towards the pancreatic islet. However, a more complex model than 
one single environmental factor might be required to explain disease onset; indeed, T1DM progresses 
through multiple stages, each of which could be influenced by one or multiple environmental triggers 
[16]. A number of environmental agents have been associated with enhanced risk for the disease; 
moreover, the rising incidence of the disease suggests that there is a corresponding increase in exposure 
to such factors. Viral infection is one such factor, and has been heavily investigated for correlation with 
T1DM. Indeed, the seasonal peak of enterovirus infections parallels a seasonal rise in incidence of T1DM 
[9]. Specifically, antibodies against the Coxsackie B family of enteroviruses have been identified as being 
present in recent-onset T1DM patients. However, direct measurement of intra-islet viral presence is 
difficult to attain in a non-invasive fashion. Although viral infection is the most well-studied non-genetic 
factor associated with vulnerability for T1DM, numerous others have also been suggested to have the 
ability to modify disease risk. These include climate, vaccine administration, psychological stress, early 
infant diet, exposure to dietary or environmental toxins, sun exposure, and population hygiene [17]. 
 
III. Prevention/ Interventions against Overt T1DM 
 In recent years, a widespread effort has been focused on prevention of T1DM in pre-diabetic 
individuals, in addition to disease-abrogating therapies targeted towards overt diabetics. Recent-onset 
diabetes patients are the most frequent population that such therapies have been tested on. A number 





investigated in human clinical trials, but none have yet seen permanent remission from disease and such 
trials confer a number of limitations. There are currently no biomarkers that correlate with disease 
progression, and endpoints for clinical trials are often limited to analysis of β-cell function after a pre-
defined period of time [16]. Furthermore, non-invasive techniques to analyze β-cell mass have not yet 
been developed, which prevents direct measurement of therapy effectiveness within the islet. Stem cell 
transplantation and islet transplantation are noteworthy potential therapies for T1DM, but outcomes 
with these have been overall unsuccessful; the transplanted islets end up susceptible to the same 
destructive autoimmune attack as the endogenous islets. Although overt diabetics transplanted with 
healthy islets or pancreata have remained insulin-free for a period of time, they often endure a rigorous 
regime of immunosuppressant drugs to prevent autoimmune attack on newly-transplanted cells [18].  
Prevention trials are of interest in the diabetes community, especially among individuals 
identified as high-risk in regards to T1DM development. First-degree relatives of a Type 1 diabetic who 
test positive for one autoantibody have a less than 20% risk for disease development, whereas the 
presence of two or more circulating autoantibodies confers a 90% risk [16]. However, as in trials for 
overtly diabetic individuals, prevention trials have also presented with disappointing results. Participant 
recruitment requires screening of a large number of people, since autoantibody frequency among 
relatives of Type 1 diabetics is only about 3.5%. Moreover, individuals who do enroll in such trials must 
not have already undergone islet autoimmune attack, and experimental conditions must be exact in 
regards to dosing of the given experimental agent [16]. Before implementation of a successful 
prevention for pre-diabetics or therapy for overt diabetics, a number of barriers need to first be 
overcome. Centrally, the autoimmune trigger and mechanism of β-cell death are still unclear; without a 






Elucidation of the β-cell death mechanism has proven challenging to investigators; although it 
still remains unclear, a number of proteins and pathways have been suggested to have a role in the 
process. Controversy resounds in both the proposed intracellular signaling pathway and whether this 
pathway should be classified as an apoptotic or non-apoptotic event [19-21]. Two signaling pathways in 
particular have been investigated for a role in β-cell death; Fas receptor and the perforin/granzyme 
pathway have critical function in maintenance of immune homeostasis and in mediation of target cell 
death. Although research into the role for perforin/granzyme in development of T1DM has been 
relatively consistent in that it likely mediates the effector phase of β-cell death, the role for Fas is more 
obscure. The signaling pathway initiated by interaction between Fas and Fas ligand (FasL) has been 
shown to be both dispensable and indispensable for β-cell death and development of T1DM, although a 
number of separate genetic backgrounds, mutations, and transgenic models have been used to derive 
these results. This is significant in that each of these model systems might confer separate mechanisms 
of β-cell death, and could explain the inconsistencies in Fas β-cell research. This literature review was 
undertaken with the intent of reconciling the current state of the Fas β-cell death field. Extensive 
searches were conducted to compile all relevant literature (Appendix: Figure 3, Tables 3 & 4), which 
was subsequently organized and analyzed based on each group’s choice of model system to test a 
similar hypothesis. Each mutation or transgene used in Fas β-cell literature was examined for reported 
findings, in addition to strengths and limitations in the context of usefulness for investigation of Fas-
mediated β-cell death. To date, there is no single document that summarizes the research relevant to 
Fas signaling in β-cell death; this document will be innovative in that it will be the first to do so, and will 
provide a comprehensive reference for researchers interested in investigating the role for Fas-FasL 













Type I diabetes mellitus (T1DM) is a chronic autoimmune endocrine disorder that continues to 
increase in incidence, and confers an enhanced risk for a number of long-term health consequences. 
Although innumerable groups have continued for years to investigate its pathogenesis, the mechanism 
of how immune-mediated β-cell death occurs is still unclear. A number of proteins capable of mediating 
cell death have been implicated in this process [22], one of which is the Fas receptor (also known as 
CD95/APO-1). Interaction between Fas and its respective Fas ligand (FasL/CD95L/APO-1L) has already 
been established as critical for homeostasis among cellular populations of the immune system, as well 
as in maintenance of immune privilege in some tissues. Because FasL is expressed on the surface of 
activated lymphocytes, it is possible that FasL on autoreactive islet-infiltrating cells could mediate 
pancreatic β-cell death through interaction with β-cell surface Fas. The ability of Fas to be induced to the 
β-cell surface strongly supported this notion [23], and was further investigated with the demonstration 
that diabetes-prone mice with a systemic deficiency in Fas or FasL are protected from diabetes 
development [24, 25]. However, the absence of Fas-FasL interactions for maintenance of immune 
system equilibrium results in a number of physiological abnormalities that affect its natural response to 
an autoimmune trigger.  
 The problems inherent to a systemic Fas deficiency were circumvented by multiple groups that 
generated new methods for investigating Fas-FasL interactions in the islet β-cell, without depleting its 
function in hematopoietic tissues. However, this resulted in a field comprised of animals and cell lines 
from separate genetic backgrounds coupled with knockout mutations and transgenic overexpression, of 





 If Fas is indeed critical for β-cell death, interruption of the interaction between β-cell Fas and 
immune cell FasL should confer a level of protection against β-cell death and ultimately development of 
T1DM. This review aims to characterize the role of Fas-FasL interactions in both physiological 
homeostasis and in β-cell pathology leading to T1DM, and will investigate the proposed links between 
its known homeostatic functions and its potential ability to mediate autoimmune pathogenesis leading 
to T1DM. Additionally, we will identify and relate the studies of Fas/FasL on β-cell death by presenting 
their findings, inconsistencies in relation to each other, and alternative approaches for therapeutic use 
of Fas-FasL in protection of the β-cell from autoimmune-mediated death. From these findings, future 
investigators interested in the role for Fas and FasL in β-cell death will be better equipped to choose an 
appropriate model system for derivation of findings that could ultimately translate to therapeutic 
interventions. 
 
II. Characterization of Fas & FasL 
General Mechanism of Action 
Discovery of the Fas receptor was preceded by the synthesis of two monoclonal antibodies that 
recognized the same target receptor; both had cytolytic activity in a variety of human cell types, and 
were termed anti-APO-1 (apoptosis antigen 1) and anti-Fas [26, 27]. Isolation of  cDNAs encoding the 
antigen to anti-Fas led to identification and characterization of the Fas receptor [28], whose gene lies on 
human chromosome 10q24.1 [29], and on its homologous mouse counterpart chromosome 19 [30]. 
Characterization of the APO-1 antigen and its nucleotide sequence revealed that it lay on chromosome 
10q23 [31] and shares sequence identity with Fas antigen gene [26]; hence, the terms Fas and APO-1 are 
often used interchangeably.  
The Fas protein is a trimeric receptor that is a member of the death receptor (DR) subfamily and 





subfamily share a cysteine-rich extracellular domain and a cytoplasmic region, which is referred to as a 
death domain (DD), and is required for apoptotic signal transduction upon receptor activation [33, 34].  
Additionally, the receptor is characterized as a type I transmembrane protein due to the location of its 
extracellular N-terminal and intracellular C-terminus [28]. The cytolytic activity initiated by binding of 
anti-Fas to its receptor suggested that Fas might have a natural ligand which communicates an apoptotic 
signal. Indeed, the Fas ligand (FasL/CD95L/APO-1L) was first identified on the surface of a cytotoxic T cell 
hybridoma by use of soluble Fas antigen [35], and soon after confirmed to be the ligand specific for Fas 
receptor; activation of the receptor induced cytotoxic activity against Fas-expressing cytotoxic T 
lymphocyte (CTL) hybridomas but not against those lacking Fas activity [36].  
FasL is a member of the TNF family whose gene resides on human and mouse chromosome 1 
[37, 38], and is classified a type II transmembrane protein due to the presence of an internal 
hydrophobic domain and a COOH-terminal region that resides outside the cell [8]. Although it occurs 
naturally in a membrane-bound form (mFasL), mFasL cleaved by metalloproteinases results in a soluble 
form of the ligand (sFasL), which can exist as a trimer [39, 40]. Whereas sFasL can still bind Fas, mFasL is 
a much more potent stimulus for cytotoxic activity than sFasL. [41-43]. In fact, sFasL has been shown to 
promote autoimmunity, tumorigenesis, and protection from the apoptotic effects of mFasL [44, 45], 
although it can still function as a death effector [40].  
Fas-FasL interactions occur in an autocrine or paracrine fashion through one of three types of 
interactions [8]:  
1. trans interaction; Fas and mFasL, expressed on the surface of distinct cells, cross-link to 
mediate death of the Fas-expressing cell. 






3. sFasL binds to Fas expressed on the same cell sFasL is released from (cis), or sFasL binds to Fas 
on the surface of a neighboring cell (trans).  
Binding of FasL to its receptor induces trimerization of Fas and initiates a conformational change 
within the cytoplasmic death domain that promotes association of an intracellular Fas-associated death 
domain (FADD), pro-caspase-8, and the caspase-8 regulator cellular FLICE-like inhibitory protein (cFLIP); 
these together comprises the death-inducing signaling complex (DISC). Although cFLIP is most 
commonly an anti-apoptotic molecule, the cFLIP long (cFLIPL) isoform can support cell death [46]. The 
FADD promotes oligomerization of procaspase-8 and through autoproteolysis is subsequently released 
as active caspase-8 into the cytoplasm [46]. At this stage of the apoptotic pathway, the type of cell in 
question determines how the pathway will proceed; this can be either directly through an extrinsic 
pathway (type I cell) or indirectly through an intrinsic mitochondrial pathway (type II cell) [47](Figure 2). 
Cell types such as thymocytes, activated T cells, and B lymphoma cells characterize the type I cell 






[48], whereas hepatocytes and β-cells are classified as type II cells [49, 50]. X-linked inhibitor of 
apoptosis (XIAP) is the only member of the mammalian IAP protein family that directly inhibits caspases 
and acts on the effector caspases -3 and -7 [51]. This mechanism discriminates between type I and type 
II apoptosis, because the absence of XIAP causes hepatocytes to undergo apoptotic death independent 
of the mitochondrial pathway [52, 53]. In contrast with type I cells, type II cells have much lower levels 
of Fas-dependent DISC formation and subsequent caspase-8 activation [46]. The limited availability of 
active caspase-8 in type II cells prevents accumulation of adequate quantities of cleaved caspase-3 for 
facilitation of apoptosis; such quantities of caspase-8 are, however, sufficient to cleave Bid and allow 
type II cells to progress through the intrinsic mitochondrial pathway [54, 55].  
Downstream of caspase-8 activation, type II cells proceed through a mitochondrial pathway 
initiated with caspase-8-mediated cleavage of the BH3-only protein Bid. Newly-cleaved tBid, facilitated 
by interaction with mitochondrial carrier homologue 2/Met-induced mitochondrial protein 
(MTCH2/MIMP), translocates to the mitochondrial outer membrane to activate the pro-apoptotic 
proteins Bax/Bak [56]. Bax/Bak mediate mitochondrial outer membrane permeabilization (MOMP), 
releasing a second mitochondria-derived activator of caspase/direct IAP binding protein with low pl 
(Smac/DIABLO) [57], cytochrome c, and other apoptogenic factors from the mitochondria. In the 
presence of ATP, cytochrome c binds apoptotic protease activating factor-1 (APAF-1) to form the 
apoptosome; recruitment of inactive caspase-9 to the apoptosome leads to its autoactivation, allowing 
it to cleave caspase-3 [58]. Additionally, the XIAP antagonist Smac/DIABLO promotes caspase-3 cleavage 
by blocking XIAP-caspase-3 binding [51, 53](Figure 2).  
By contrast, type I cells use caspase-8 to directly cleave and activate caspase-3 [53]. Active 
caspase-3 induces proteolysis of structural proteins and other essential cellular components, leading to 





their apoptotic activities, survival pathways may also be initiated; however, these concepts are beyond 
the scope of this article (see Ref. [59-62] for further review).  
 
Constitutive Expression  
 
The Fas receptor is constitutively expressed in a variety of tissues throughout the body, with 
abundant expression in the thymus, liver, ovary, and heart [30]. Fas mRNA expression has also been 
demonstrated in thymocytes, where activation of mature T and B cells promotes Fas cell surface 
induction [63, 64].  
Because of its ability to induce death in Fas-expressing cells, FasL tissue expression is tightly 
controlled. FasL mRNA is constitutively expressed in a select range of tissues, centrally splenocytes and 
thymocytes, and its cell surface expression can be induced after activation of T lymphocytes and natural 
killer (NK) cells [35, 39]. FasL mRNA has also been demonstrated at low levels in mouse lungs, small 
intestine, kidney, and liver [65, 66], and the protein is constitutively expressed on the cell surface of 
immune-privileged tissues such as the eye, testes, and thymus [66, 67].   
 FasL assists in maintaining immune privilege in a number of tissues, where its constitutive 
expression at the surface of such sites can induce apoptosis in activated Fas+ infiltrating lymphocytes 
[66-68]. Immune privilege is generally defined as a situation in which a tissue is protected from immune 
infiltration, even during foreign invasion, as the proinflammatory immune response would be more 
destructive than its foreign target [69]. The eye is the most well-characterized site of immune privilege 
and multiple studies support a role for FasL in prevention of immune infiltration in the eye [66, 67]. 
Additionally, the cornea has an 80-90% transplantation success rate with no immunosuppressant use 
[69], and FasL expression is required for corneal graft survival  [70]. Studies in the testes have shown 
similar results; loss of FasL expression in testicular grafts transplanted under mouse kidney capsule 






 The concept of immune privilege has also been extended to tumor cells that express FasL and 
are therefore resistant to lymphocyte invasion, supporting a role for FasL in tumorigenesis [71, 72]. 
Inhibition of FasL expression in murine colon tumor cells suppresses tumor growth and formation and 
increases lymphocyte infiltration [73], indicating that tumor FasL expression encompasses both 
defensive and offensive strategies for tumor survival. However, controversy surrounds the role of FasL in 
tumor immune escape, likely stemming from transplantation studies in which FasL overexpression can 
cause rejection of tissue transplants [72]; although beyond the scope of this article, the interested 
reader is directed to Ref. [74] for further review. 
 
Role in Immune Homeostasis   
 
 Immune homeostasis is known as the capability of an organism to maintain equilibrium among 
cells of hematopoietic origin. One of the important roles for Fas-FasL interactions is in maintenance of 
immune homeostasis by preventing overgrowth in this cellular population, and is particularly significant 
for CD4+ and CD8+ T lymphocytes [75-77]. CD4+ T cells are referred to as helper T (TH) cells and shape 
adaptive immune responses by producing cytokines and enhancing expression of costimulatory factors. 
CD8+ T cells, in contrast, are known as cytotoxic T (TC) cells due to their direct role as cytotoxic effectors 
against target cells, but are also capable of cytokine production [78].  
 To mount an appropriate T cell-mediated response, the immune system first requires a method 
of antigen recognition. This is accomplished by a high-affinity interaction between the T-cell receptor 
(TCR)/CD3 complex with MHC-associated antigenic peptide [79]. Appropriately regulated lymphocyte 
growth and maintenance are critical for prevention of recognition of self antigens and initiation of 
autoimmunity. 
 Differentiation from a multipotent hematopoietic stem cell to mature T cell is a complex process 
that requires a coordinated effort by various transcription factors and regulatory mechanisms. Although 





thymocytes and can eventually become self-restricted single positive (SP) CD8+ or CD4+ T lymphocytes 
[80].  
On arrival to the thymus, T cell precursors do not express any of the characteristic cell surface 
markers of a mature T cell; additionally, approximately 95% of mouse thymocytes express the Fas 
protein on their cell surface [81]. A period of rapid proliferation continues through the first two of four 
double negative (DN) stages of development (CD4- CD8-), all of which are characterized by the 
coordinated expression of specific cell surface markers [82]. DN2 thymocytes begin the rearrangement 
of a T cell receptor TCR-β chain and conclude the process of somatic recombination upon progression to 
the DN3 stage [79, 83]. 
Progression to the DN3 stage indicates commitment to the T cell lineage [80], and the DN4 stage 
is a period of rapid proliferation preceding transition to double positive (DP) thymocyte which confers 
cell surface expression of both the CD4 and CD8 coreceptors [84]. TCR-α chain rearrangement, occurring 
at the conclusion of this final proliferative stage, marks TCR completion and movement to the rigorous 
process of thymic selection, from which only 5% of the original thymic population emerge as mature T 
cells [84]. Thymic selection comprises three checkpoints that must all be cleared for a thymocyte to 
become a mature T cell: death by neglect, positive selection, and negative selection.  
 Death by neglect occurs alongside positive selection, and is a passive form of cell death 
in which a cortical thymocyte fails to receive necessary signals for survival, as its TCR has not ligated with 
MHC-self peptide. The vast majority of cortical thymocytes, approximately 90%, die during positive 
selection, specifically by failing to receive survival signals that are transmitted upon cross-linking of TCR 
with MHC-self peptide [84].      
Characterized by MHC restriction, positive selection ensures that the mature T cell can recognize 
self-MHC complexes, a necessary quality for eliciting an immune response against a foreign antigen. TCR 





be recognized by the DP thymocyte. Thymocyte TCR cross-linking with MHC-self antigen promotes 
thymocyte survival and movement to the next stage of thymic selection [82]. 
 In contrast to positive selection, negative selection only clears approximately 5% of the initial 
thymocyte pool [84] but is fundamental to prevention of an autoimmune response. Negative selection is 
characterized by high-affinity engagement of the thymocyte TCR with self-MHC from dendritic cells (DC) 
or medullary epithelial cells, resulting in apoptotic death; only moderate-affinity interactions between 
TCR and MHC-self peptide allow for survival during the negative selection process.  
 Although not critical for thymic negative selection [85-87], Fas-FasL interactions are 
indispensable for peripheral selection, or post-maturation hematopoietic cell deletion, and maintenance 
of immune homeostasis. This was illustrated by loss-of-function mutations in both Fas receptor and Fas 
ligand. Lymphoproliferation (lpr) is an autosomal recessive mutation in the Fas receptor that was first 
identified in MRL/MpJ mice and has since been localized to mouse chromosome 19 [88, 89]. Generalized 
lymphoproliferative disorder (gld) is a mutation in FasL that originated in the C3H/HeJ mouse strain [90] 
on mouse chromosome 1 [38], and although nonallelic to lpr, produces nearly identical serological and 
immunopathological markers as lpr on the same mouse strain. These mutations were originally 
postulated to be involved in metabolic cycling until bone marrow transfer experiments conducted by 
Allen et al. suggested that they might be mutations in a pair of interacting molecules, such as that of 
receptor and ligand [91]. Indeed, genetic mapping analysis showed that lpr is located in close 
chromosomal proximity to the Fas receptor [92], and gld to that of the Fas ligand [38]. lpr is thus a 
mutation in Fas receptor and gld a mutation in Fas ligand, discoveries made through comparison of wild-
type (wt) and mutant cells for Fas and FasL gene expression [38, 92].  
The lpr mutation occurs as a result of premature splicing due to insertion of a early transposable 
element (ETn) containing two poly-A adenylation sites at the long terminal repeat (LTR) region within 





before exon 3, resulting in limited expression and function of the Fas receptor in both MRL/MpJ and 
CH3/HeJ mice [92].  However, lpr is a leaky mutation; Fas receptor can be expressed in lpr/lpr mice, at 
approximately 1-2% of the wild-type level [94]. FasL is constitutively expressed and fully functional in 
lpr/lpr mice [95]. lprᶜᵍ, a dominant-negative mutation that is allelic to lpr, was originally detected in 
mutant mice from the CBA/K1 mouse strain [96] and is known as ‘lpr complementing gld’ due to its 
ability to induce weaker lymphadenopathy than lpr/lpr when the heterozygous gld/+ mutation is also 
present [97]. lprᶜᵍ also blocks functional Fas expression, but through a point mutation in the cytoplasmic 
apoptotic signal-transducing region of the Fas gene. Although lprᶜᵍ Fas is expressed at similar levels as 
wild-type, the receptor cannot transmit a death signal and is thus nonfunctional [81, 92].  
gld, the loss-of-function mutation in FasL, is characterized by a point mutation within the 
extracellular region of the FasL [38]. Unlike lpr, which limits Fas expression, gld still confers FasL 
expression. And although it has a low level of function, FasL in gld/gld mice displays the same 
constitutive expression pattern as in lpr/lpr mice [95, 98].  
The physiological and etiological implications of homozygosity for lpr/lpr and gld/gld are nearly 
the same. Both mutations incur massive lymphoproliferation and progressive infiltration of the spleen 
and lymph nodes with nonmalignant double negative (DN) CD4-, CD8-, and Thy1+ T cells, as well as 
increased cell surface expression of B220, which is normally expressed on B cells, and other abnormal T 
cell-surface markers [99], all of which manifest in an age-dependent manner [99]. Enhanced production 
of autoantibodies such as anti-ssDNA, IgG, and IgM [100] in lpr/lpr and gld/gld mice, links these murine 
mutations to their closest human syndrome, an autoimmune disease known as systemic lupus 
erythematosus (SLE) [101]. Another such disorder, autoimmune lymphoproliferative syndrome (ALPS), 
often confers a mutation in the Fas gene and results in symptoms similar to that seen in lpr/lpr mice 
[102]. Finally, the lpr gene is fittingly expressed in bone marrow hematopoietic stem cells [99], the site 





The immunological implications of lpr/lpr and gld/gld, coupled with the demonstration of Fas 
receptor expression on the cell surface of activated B and T cells [64, 103], led to the postulation that 
Fas-FasL interactions play a critical role in immune homeostasis [87, 92, 104]. Studies conducted with 
both lpr/lpr and Fas¯/¯ mice indicate an obligatory role for Fas in peripheral clonal deletion, as 
evidenced by lymphocyte accumulation in the spleen and lymph nodes of the mutated mice [86, 87, 
105]. Additionally, when the Fas transgene is expressed in lpr/lpr mice the lymphoproliferation 
phenotype is abolished, reinforcing the indispensable role of Fas-FasL interactions in peripheral deletion 
[106]. 
Another critical role for Fas-FasL interaction in the immune system is the ability to mediate 
target cell death by signaling from CTLs and NK cells; this is in combination with other mechanisms, 
namely the perforin/granzyme pathway, in which exocytosis of perforin granules and granzyme B from 
the CTL causes target cell death  [8, 22, 107, 108]. Although their method of target cell recognition are 
different, CTLs and NK cells kill by the same lytic mechanism [109]. Naïve lymphocytes store FasL in 
intracellular lytic granules [110], and TCR/CD3 lymphocyte stimulation causes FasL localization to the 
immunological synapse [111]. This event is controlled by a proline-rich domain in the cytoplasmic tail of 
FasL, and is critical for prevention of constitutive FasL on the surface of activated cytotoxic cells. Ligation 
of cell surface FasL to target cell Fas then initiates the signaling cascade as described above (Figure 2). 
Conclusion of this cytotoxic activity and the expansion phase mark the start of a contraction phase, 
whereby immune cells begin undergoing activation-induced cell death (AICD) to bring the cell numbers 
down to normal levels [112] and prevent overgrowth that is seen in homozygous lpr/lpr and gld/gld 
mice.   
Antigen-presenting cells (APC) are another type of immune cell, which present antigen on their 
cell-surface MHC complex for interaction with TH and TC cells and have the ability to secrete cytokines; 





macrophages. B lymphocytes are most easily distinguished from T lymphocytes by the presence of the 
CD40 B cell receptor (BCR), a membrane-bound immunoglobulin that is heavily involved in activation 
and determination of cell fate [113]. In addition to their function as APCs, B cells can produce antibodies 
to enable cytotoxic activity. Fas expression has been detected on B cells, albeit to a lesser extent than T 
cells [64], with a marked increase in cell surface expression upon activation and corresponding increase 
in sensitivity to Fas-mediated lysis [114]. Fas-mediated B cell elimination is critical for homeostasis, 
where its absence leads to autoimmune manifestations such as hyperimmunoglobulinemia and 
splenomegaly [115]. In conclusion, these data indicate an essential role for Fas-FasL interactions in APC 
elimination and B cell-mediated target cell death; however, Fas-FasL probably acts in concert with other 
known death effectors.  
    
 
III. Role of Fas Signaling in β-Cell Death 
  
 Failure to appropriately regulate the immune system’s autoreactive T cell repertoire can 
promote autoimmune disease. A classic example of this occurs in type 1 diabetes mellitus (T1DM), a 
common endocrine disease that is characterized by selective immune-mediated destruction of insulin-
secreting pancreatic β-cells [116]. T1DM development is initiated with insulitis, a term describing 
immune cell accumulation in both the periphery as well as within the islet of Langerhans. This immune 
cell invasion is followed by an effector phase whereby leukocytes recognize exposed β-cell antigens 
presented by MHC complexes on the surface of APCs within the islet and instigate β-cell death [117]. 
Both CD4+ and CD8+ CTLs are critical for autoimmune-mediated β-cell death [118, 119]. In support of 
this, immunohistological analysis has shown leukocytic islet infiltrates to be mostly composed of T cells 
[116]; CD4+ lymphocytes are the central effector in this process [120, 121]. DCs and macrophages, also 
present in the islet infiltrate, are the first invaders that trigger the adaptive immune response, typically 





lymphocytes and resident macrophages secrete IL-1β and by virtue of signaling through the IL-1 
receptor (IL-1R) on the islet β-cell surface, produce key intracellular events in the development of 
insulitis and β-cell death. Moreover, when primary islets or insulinoma cell lines are exposed to IL-1β 
alone or IL-1β combined with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), there 
is a loss of cellular function as measured through GSIS and eventual progression to cell death [19-21, 
123, 125, 126]. Finally, IL-1β-stimulated increases in the inducible form of nitric oxide synthase (iNOS), 
which catalyzes production of nitric oxide (NO), likely acts as a direct mediator of β-cell death [21, 127-
129]. However, the molecular mechanism underlying cytokine-mediated β-cell destruction is still not 
well understood. Although MHC class II expression on autoreactive CD4+ lymphocytes is normally 
required for autoantigen recognition, its expression has not been observed on islet-invading CD4+ 
lymphocytes [130]. Additionally, it is unlikely that there is one single effector mechanism of β-cell death, 
and likely varies amongst species and even individuals. Multiple proteins capable of instigating cytotoxic 
intracellular signaling might have a role in the process, with evidence implicating perforin/granzyme, 
TNF/TNFR1, and Fas-FasL [6, 7, 22, 24, 131-133]. 
The majority of studies investigating the mechanism of β-cell death and development of T1DM 
have focused on a potential role for Fas-FasL interactions. Although Fas and FasL do not contribute to 
genetic susceptibility for T1DM [134-136], their interaction was initially implicated in β-cell death when 
autoimmune diabetes-prone non-obese diabetic (NOD) mice carrying the lpr/lpr mutation failed to 
develop diabetes [24, 25]. Adoptive transfer of diabetogenic CD8+ islet-specific T cells or total 
splenocytes also failed to induce diabetes in Fas-deficient lpr/lpr mice [24, 25].  Moreover, IL-1β-induced 
β-cell-surface Fas expression could provide a mode of β-cell death by Fas receptor activation [23]. These 
findings led to the commencement of a span of studies that explored the role for Fas-FasL interactions in 
β-cell death, yet the complexities involved with islet physiology have made it difficult to conduct in vivo 





patient (Tables 1 & 2), and have majorly contributed to the inconclusive and conflicting results of 
subsequent Fas β-cell death studies. This review summarizes the progression of the Fas β-cell field by 
reporting the ex vivo genetic manipulations and transgenic models, and whether or not these confirm a 
















































Method of diabetes 
induction 
Mutation/Transgene Reference 





lpr/+ [24, 138, 140] 
gld/+ [139, 141] 
IL-10R-neutralized-gld/+ [142] 
IL-10-transgenic-lpr/lpr [143] 











Neutralizing anti-Fas Ab 
at 2-4 weeks old 
[151] 



















CD8+ T cell-mediated RIP-SOCS-1.NOD8.3 [157] 
Table 1. Summary of mutations and transgenes that comprise 
spontaneous and pharmacologically-induced models used for 
investigation of Fas-mediated β-cell death. 












Cell Type Splenocytes Pancreatic Islets 
Genetic 
Background 
Donor Recipient Reference Donor Recipient Reference 
 NOD-wt NOD-lpr/lpr [24, 139, 
140] 
NOD-wt diabetic NOD-wt [137] 
NOD-wt NOD-scid/scid [141] NOD-wt diabetic NOD-wt* [158] 
NOD-wt NOD-scid/scid-
gld/gld 
[141] NOD-wt male NOD-wt** [137] 
diabetic NOD-wt NOD-wt* [151, 152] C3H/HeJ-wt NOD-wt** [159] 
diabetic NOD-wt NOD-scid/scid-
lpr/lpr 
[138, 139] NOD-lpr/lpr NOD-wt [152] 
SA-FasL from diabetic NOD NOD-wt [160] NOD-lpr/lpr male NOD-wt** [137] 
IL-10-transgenic NOD-lpr/lpr NOD-scid/scid [143] NOD-lpr/lpr diabetic NOD-wt [137] 
NOD-lpr/lpr NOD-scid/scid [143] C3H/HeJ-lpr/lpr NOD-wt [159] 
NOD-gld/+ NOD-scid/scid [141]  
Cell Type CD8+ islet-specific T cells CD4+ islet-specific T cells 
Genetic 
Background 
Donor Recipient Reference Donor Recipient Reference 
 NOD-wt NOD-lpr/lpr [25] NOD-wt NOD-wt [151] 
NOD-wt NOD-wt* [151] YNK7.3 clones, no 
donor 
NOD-lpr/lpr [151] 
HA-specific from Balb/c 
clone-4 TCR transgenic 
Balb/c Ins-HA-
lpr/lpr 
[161] HA-specific from TCR-
HA transgenic RAG-2¯/¯ 
INS-HA-RAG-2¯/¯ [153] 
OVA-specific from OT-1 TCR 
transgenic 
B6.MRL-lpr/lpr [162] HA-specific from TCR-




NOD-8.3 from NOD-lpr/lpr  NOD-8.3 [163]  
Table 2. Summary of adoptive transfer models from in vivo studies that investigated the role of Fas-FasL interactions 
in β-cell death. 
 *Treated with a neutralizing/antagonist anti-FasL antibody 





lpr & gld, Loss-of-Function Mutations 
 
Although the original lpr/lpr mouse was identified in the MRL/MpJ mouse strain, the mutation is 
often transferred to the non-obese diabetic (NOD) mouse for β-cell studies investigating the 
contribution of the Fas receptor. The NOD mouse is the most frequently used murine model for diabetes 
studies because it develops the disease in a T cell-dependent manner that is reminiscent of a human 
T1DM patient [164, 165]. There is a difference in rate of diabetes onset between male and female NOD 
mice. Females have decreased insulin content at 12 weeks of age and a 90-100% diabetes incidence by 
30 weeks old; males have a 40-60% incidence by the same age. Female NOD mice are thus more 
appropriate for spontaneous diabetes studies, whereas males are well-suited for studies of accelerated 
disease transfer (Jackson Labs website). Fas expression is elevated in female NOD mice at 15 weeks of 
age relative to their male counterparts and correlates with the overall gender difference observed in 
NOD mice  [166]. Similar to the MRL-lpr/lpr model, NOD-lpr/lpr mice develop lymphadenopathy and 
massive infiltration of nonmalignant DN CD4- and CD8- T cells [24, 138].  
The initial studies implicating Fas-FasL interactions in β-cell death showed that NOD-lpr/lpr mice 
failed to develop spontaneous diabetes as compared with their wild-type littermates [24, 25]. FasL-
deficient NOD-gld/gld mice were also protected from diabetes development [138]. Further, adoptive 
transfer of CD8+ islet-specific T cells or diabetogenic splenocytes from NOD-wt donor mice to NOD-
lpr/lpr mice failed to initiate diabetes, and together these studies indicated a significant role for Fas-FasL 
interactions in development of autoimmune diabetes [24, 25]. The lprᶜᵍ mutation is less commonly used 
in Fas β-cell studies, but one group showed some protection from development of spontaneous 
diabetes amongst NOD mice carrying the lprᶜᵍ mutation, which was driven by the rat insulin promoter 
(RIP) and thus confers β-cell-specific expression; the extent of diabetes protection was dependent on 
the level of transgene expression [139]. This is a significantly different observation from the lpr/lpr and 





prevention of autoimmune-mediated β-cell destruction, as opposed to diabetes prevention by loss of 
Fas specifically in the β-cell. 
The validity of the lpr/lpr mouse as a reliable model for Fas β-cell studies has been subsequently 
questioned [137, 140]. The systemic Fas deficiency introduced by a homozygous lpr/lpr mutation may 
prevent diabetes, not due to absence of Fas from β-cells, but as a consequence of an inappropriately 
functioning immune system that cannot generate a normal inflammatory response [137, 138, 140, 152]; 
abnormal CD4- CD8- B220+ cells of NOD-lpr/lpr mice are also more resistant to sublethal irradiation 
relative to their NOD-wt counterparts [167]. Additionally, failure of adoptively transferred splenocytes 
to initiate diabetes in recipient NOD-lpr/lpr mice occurs as a result of constitutive FasL expression on 
endogenous lymphocytes, which arises as one of multiple abnormalities resulting from the lpr/lpr 
mutation. FasL overexpression on NOD-lpr/lpr lymphocytes kills diabetogenic Fas-expressing cells 
through cell surface Fas-FasL interactions before diabetes can be transferred to the recipient mouse 
[137, 140]. Furthermore, localization of the gld/gld mutation to hematopoietic tissues by adoptive 
transfer of gld/gld bone chimeras into NOD-wt mice results in DN lymphoproliferation, demonstrating 
that FasL deficiency on immune cells is the cause of the abnormal phenotype that occurs in gld/gld mice 
[141]. In order to circumvent the confounding immunological effects of the NOD-lpr/lpr and NOD-
gld/gld mouse, alternative genetic alterations and methods of diabetes induction such as islet 
transplantation and heterozygosity for lpr and gld have been developed and will be described below.  
 Interestingly, the abnormal phenotype associated with homozygosity for lpr and gld is not 
evident in mice that are heterozygous for either mutation. Heterozygotes behave in a comparable 
fashion to wild-type mice; whereas NOD-lpr/lpr mice fail to develop diabetes, NOD-lpr/+ develop 
diabetes at a similar rate to wild-type mice [24, 140]. Further, although NOD-gld/+ mice have a 0% 
incidence of spontaneous diabetes, they have normal-sized lymphoid organs and don’t develop 





indicates that these mice have a sufficient decrease in FasL expression to prevent β-cell death, but there 
is adequate FasL expression to prevent the immune implications that result from a complete loss of FasL  
[141].  
IL-10 is an anti-inflammatory cytokine that has a significant role in growth and differentiation of 
various hematopoietic cells and can prevent onset of some inflammatory conditions [168]. Although its 
involvement in T1DM development is ambiguous, IL-10 might be protective against diabetes 
development in NOD-gld/+ mice. Neutralization of pancreatic B cell-surface IL-10 receptor (IL-10R) 
causes a mostly CD4+ T cell-comprised islet cell infiltration, but not transition to diabetes [142]. 
However, this protective effect is likely specific to NOD-gld/+ mice that do not naturally develop 
diabetes, as blocking of the IL-10R in NOD-wt mice has little consequence on insulitis or diabetes 
incidence. Additionally, β-cell-specific gene transfer using recombinant adeno-associated virus vector 
(AAV) for IL-10 in NOD-wt mice has little protective effect against diabetes development [169]. These 
recent findings corroborate the above results in NOD-wt mice yet dispute the IL-10-mediated diabetes 
protection observed in NOD-gld/+ mice. Moreover, another group actually reported an acceleration of 
NOD diabetes when made transgenic for IL-10. They showed that this acceleration was independent of 
Fas, in that NOD-lpr/lpr mice were not protected from IL-10-induced diabetes. Splenocytes from these 
mice were able to transfer diabetes to NOD mice deficient in T- and B-lymphocytes by the severe 
combined immunodeficiency (scid) mutation (NOD-scid/scid), in contrast to their non-IL-10-transgenic 
NOD-lpr/lpr counterparts that could not cause this induction [143]. Yet lymphocytes from NOD-gld/+ 
mice still carry diabetogenic potential, as NOD-scid/scid mice reconstituted with splenocytes from NOD-
gld/+ or NOD-wt mice develop diabetes at similar rates to each other [141].  
A novel approach of analyzing the NOD-gld/gld mouse was taken by separating FasL expression 
in the hematopoietic and nonhematopoietic compartments of NOD-gld/gld mice and showed that 





experiments in which wild-type splenocytes failed to cause diabetes in NOD-scid/scid-gld/gld mice with 
a systemic deficiency in FasL and the T- and B-lymphocyte population (but are Fas-sufficient) 
demonstrated that protection from diabetes development in NOD-gld/gld and NOD-gld/+ is not a result 
of abolished β-cell Fas-FasL signaling and thus favors a Fas-independent mechanism of β-cell death  
[141].  
 Sublethally irradiated NOD-lpr/lpr mice did not develop spontaneous diabetes upon adoptive 
transfer of diabetogenic cells [24, 25, 137] because abundant FasL in NOD mice homozygous for the lpr 
mutation was likely killing the adoptively transferred splenocytes [137, 140]. Therefore, the destructive 
role of Fas-FasL interactions in murine autoimmune β-cell death was investigated by grafting islets from 
murine lpr/lpr or wild-type mice into non-diabetic NOD-wt mice. Adoptive transfer of pancreatic islets 
from lpr/lpr donor mice into wild-type recipients should confer some level of islet survival if Fas were to 
play a necessary role in β-cell death, in that absence of functional Fas on the donor islet would prevent 
initiation of the intracellular death cascade via interaction with endogenous recipient FasL. However, 
after adoptive transfer of diabetogenic splenocytes to male NOD mice that had been grafted prior with 
fetal pancreatic islets from NOD-lpr/lpr or NOD-wt mice, the NOD-lpr/lpr β-cells fared better than the 
NOD-wt islets although both were eventually destroyed [137]. While modest, these findings suggest a 
role for Fas in autoimmune β-cell destruction. Another group also reported effective destruction of 
lpr/lpr islets transplanted into NOD-wt mice, and concluded a dispensable role for Fas-FasL in β-cell 
death but did not transplant wild-type islets for comparison [152]. Injection of a neutralizing anti-FasL 
antibody (Ab) did not affect diabetes incidence after adoptive transfer of diabetogenic splenocytes or 
diabetes induction with cyclophosphamide (CY), indicating Fas-independent β-cell death. In contrast, 
treatment with a neutralizing anti-FasL Ab after syngeneic islet transplantation to diabetic NOD mice 
restored normoglycemia [158]. Additionally, CH3/HeJ-lpr/lpr islets survived as indicated by normal blood 





treatment. Although the wild-type islets were destroyed, there was evidence of CD4+ and CD8+ 
lymphocyte migration to the kidney capsule in both models, which indicates Fas-independent insulitis 
but an effector phase of β-cell death that may be Fas-dependent  [159]. Furthermore, NOD-lpr/lpr fetal 
pancreas grafts could not reverse diabetes in diabetic female NOD mice; although the NOD- 
 lpr/lpr islets fared better relative to wild-type islets, they were eventually destroyed [137].  
 Another way to reduce peripheral lymphoid populations and constitutively-expressed FasL 
conferred by the lpr/lpr mutation is to delete the potentially abnormal T and B cells altogether. This 
model requires use of the scid mutation [170]; studies investigating diabetes incidence in scid/scid-
lpr/lpr mice used mouse models of similar genetic background and diabetes induction, and were 
consistent in their reported results. Reconstitution of sublethally irradiated NOD-scid/scid-lpr/lpr mice 
with diabetogenic spleen cells conferred a significant reduction in diabetes incidence relative to NOD-
scid/scid mice that carry functional Fas [138, 139]. This could infer both Fas-dependent and –
independent mechanisms; the primary justification is that the reduction in diabetes incidence could now 
be directly attributed to absence of Fas expression. An alternative explanation is that the lpr/lpr 
mutation allows for a sufficient level of functional Fas receptor activity or that autoimmune disease in 
the adoptive transfer model can also be initiated by Fas-independent mechanisms. This would 
potentially allow for a low level of diabetes incidence. 
 Studies using the lpr and gld mutations, either alone or paired with other mutations, genetic 
models, or methods of diabetes induction, comprise the majority of the Fas β-cell field (Tables 1 & 2). 
Although the homozygous mutations alone confer a dysfunctional immune system and abnormal 
phenotype that make it difficult to directly address the role of Fas-FasL interactions in β-cell death, a 
number of groups have found ways to circumvent these abnormalities and manipulate the mutations in 
combination with other genetic modifications to investigate the mechanism responsible for 






Induction of β-Cell Surface Fas Expression 
  
Although the lpr/lpr mutation sparked initial interest in Fas-dependent β-cell death, support for 
Fas involvement was built on the ex vivo demonstration that isolated islets from both diabetic rodents 
and humans have abundant Fas β-cell surface expression [25, 131, 171-173], whereas β-cells isolated 
from disease-free organisms have negligible quantities of cell-surface Fas expression [174-176]. To 
corroborate these findings, syngeneic islets from non-diabetic donors transplanted into diabetic NOD 
mice had abundant levels of Fas expression, whereas their normoglycemic counterparts had a 
significantly lower level of Fas expression [177]. In addition, adoptive transfer of spleen cells from 
diabetic NOD donor mice conferred Fas expression in β-cells of recipient NOD-scid/scid mice [178]. 
Some murine studies, however, reported low levels of Fas expression on the β-cell surface of diabetic 
NOD and mice induced to diabetes with CY [179-181], which may reflect a species-specific preference 
for mechanism of β-cell death and/or a disparity between modes of diabetes induction. One of these 
groups later found that the low level of Fas expression in islet tissue originally reported [179] was 
actually Fas expression on leukocytes, as indicated by dual staining with anti-CD45 and Fas [178]. 
Additionally, invading mononuclear and activated T cells stain positive for Fas activity in 
immunohistochemistry studies and become apoptotic after treatment with an anti-Fas Ab, illustrating 
that autoreactive cells can also be deleted by AICD during islet infiltration [171, 176, 180-182]. An in vivo 
study in which IL-1β-deficient female NOD mice were used noted that spontaneous diabetes was not 
significantly decreased in comparison with NOD-wt [144]. In a separate experiment, the same group 
blocked IL-1β expression by creating NOD mice deficient in IL-1β-converting enzyme (ICE), which 
converts the inactive IL-1β precursor to its active form. Spontaneous diabetes was again unaffected; if 
Fas, whose expression is induced by IL-1β, were indeed the primary β-cell death effector, β-cell death 





 Cell surface FasL expression ex vivo is perhaps more perplexing in that the findings are not 
generally in agreement. FasL expression has been demonstrated in mice with insulitis [176, 180] but not 
in the pancreas of NOD-scid/scid mice after adoptive transfer of splenocytes (data not shown) [183]. 
FasL is also reported to have constitutive expression in islet α-cells [181], and β-cells of Type 2 diabetic 
patients [184] and non-diabetic human donors [175, 184]. However, other extant studies show FasL 
expression to be present on infiltrating mononuclear cells and activated CD4+ and CD8+ lymphocytes but 
not on human or mouse islet endocrine cells [131, 171, 179, 185]. One study did note the presence of 
FasL transcript from diabetic pancreata preparations, but it wasn’t clear if this was β-cell specific or from 
another pancreatic cell type [131]. 
The most commonly cited source of the general discrepancy in detection of FasL expression is 
that the anti-FasL antibodies used in these studies range in their specificities for FasL, which can confer 
false positive staining [171, 180, 186]. Additionally, detection of FasL could be impacted by 
methodological problems such as failure to account for FasL that has been cleaved from the cell surface 
or destruction of cell-surface FasL during the process of islet isolation and purification. To avoid such 
problems, studies that intend to analyze β-cell FasL expression should rigorously test anti-FasL 
antibodies for specificity before use and employ dual staining for FasL and insulin to localize its 
expression to pancreatic β-cells. 
Although ex vivo FasL studies do not conclusively establish ability for the β-cell to express FasL 
mRNA or protein, it is well-established that FasL expression occurs on the surface of activated resident 
and invading mononuclear cells to the islet during insulitis, as described above. This makes inducible β-
cell-surface Fas expression the limiting factor for potential occurrence of β-cell-immune cell Fas-FasL 
interactions, and is a critical item to address for in vitro studies that require a method of cell surface Fas 
induction. Incubation of primary islets or transformed insulinoma cell lines with pro-inflammatory 





since IL-1β is released from immune cells during islet infiltration. In vitro incubation with IL-1β also 
appears to be a reliable method of Fas β-cell surface induction. Treatment of primary human, mouse, 
and rat islets with IL-1β alone or IL-1β in combination with IFN-γ and TNF-α increases Fas mRNA 
production and promotes cell surface localization in a dose-dependent manner [23, 131, 173, 177, 187-
189]. Expression of Fas after IL-1β treatment may depend on dose and time of exposure [179]. The 
combination of IL-1β, IFN-γ, and TNF-α synergizes to enhance Fas expression, but IL-1β is likely the 
dominant signal in human and murine islets [131, 179]. A similarly strong induction of cell surface Fas 
expression can be obtained through treatment of non-diabetes-prone Balb/c mouse islets with IL-1α 
[190]. Some studies then confirmed functionality of cytokine-induced cell surface Fas by demonstrating 
an increase in apoptosis after treatment with an agonist-Fas Ab or sFasL [179, 187, 190, 191]. One group 
also noted a dose-dependent increase in Fas expression after treatment of human β-cells with glucose 
concentrations of up to 33.3 mmol/L [184] yet Fas expression on isolated rat β-cells was only observed 
on β-cells of older (7-8 mos.) rats [192]. Furthermore, glucose-induced Fas expression on rat islets is not 
enhanced by treatment with cytokines or streptozotocin treatment [193]. Interestingly, one human islet 
study noted an increase in Fas transcript expression after 96 hours amongst islet cells in culture without 
treatment, at comparable levels to islets treated with IL-1β, but incubation of the untreated islets with 
an agonist anti-Fas Ab failed to induce apoptosis [194]. This suggests that cytokines promote Fas 
accumulation at the cellular membrane leading to activation of downstream intracellular cell death 
machinery [195]. Thus, isolation of islets or conditions present in culture media can potentially impact 
baseline Fas expression.  
Unlike that reported in primary murine islets, investigation of Fas mRNA and cell surface 
expression in insulinoma cells exposed to cytokines revealed contrasting findings. RIN-5F insulinoma 
cells express Fas mRNA after treatment with IL-1β, IFN-γ, and TNF-α, as well as after exposure to 





induction of Fas cell surface expression [173, 191, 197] and total protein levels were nearly unchanged 
between untreated and cytokine-treated cells, which indicates that pre-transcribed Fas protein resides 
within the cell [191]; this intracellular store of Fas protein was also demonstrated in isolated islets from 
diabetes-prone BB/OK rats [189]. Silencing of Fas expression by small interfering RNA (siRNA) 
transfection in NIT-1 cells reduced Fas mRNA transcription by nearly 90%, and although the siRNA also 
conferred a significant decrease in cell surface Fas expression, it only reduced total protein expression 
after prolonged treatment [198]. This could indicate a slow turnover rate of β-cell Fas protein. C57BL/6 
mouse-derived β-TC1 cells exposed to Fas siRNA demonstrated a similar but less severe phenotype than 
in NIT-1 cells, in that β-TC1 cells had only a 70% decrease in Fas mRNA abundance [198]. This difference 
in mechanism thus appears to not only occur within groups, but between groups as well. Whereas NIT-1 
insulinoma cells can down-regulate cytokine-induced cell surface Fas after exposure to agonistic FasL, 
primary NOD islets and BALB/c islets do not show this response and maintain the same level of cell 
surface Fas expression with or without exposure to FasL [199]. 
In contrast to the above, another group treated the same NIT-1 cell line with IL-1α and IFN-γ, 
which induced Fas mRNA expression but did not confer cell surface expression [190]. Further, NOD 
mouse-derived MIN6N8 insulinoma cells expressed Fas mRNA in both the unstimulated and cytokine-
stimulated state, but Fas cell surface expression was not detected after treatment with IL-1β or IFN-γ 
[185]. Additionally, treatment of the MIN6N8 cells with an agonist anti-Fas Ab did not result in 
significant apoptosis, which suggests either non-functional Fas or a very low level of Fas expression.  
Studies investigating β-cell-specific Fas and FasL expression have had difficulty coming to a 
consensus on these criteria, in both the healthy and pathological state, for a number of reasons. 
Experimental problems such as β-cell specificity in immunostaining techniques and specificity of anti-
FasL antibodies for FasL present easily avoidable false-positives or –negatives. But these problems 





between primary islets and transformed cell lines. However, the ultimate ability of multiple groups to 
demonstrate Fas cell surface expression during the natural progression of diabetes in humans and mice 
was taken to mean that Fas-FasL interaction is the major mechanism of β-cell deletion.  
Because NO production is required for IL-1β-mediated cytotoxicity, it could serve as a link 
between cytokine exposure and β-cell surface Fas expression. However, a consensus on the requirement 
of NO for induction of Fas mRNA and cell surface expression has not been reached. Exposure of iNOS-
deficient murine islets to cytokines had no effect on Fas expression relative to Fas-sufficient islets [187, 
200]; and although the data was not shown, one of these groups also reported that exposure of human 
islets to the NOS inhibitor N-Methylarginine (NMMA) in addition to cytokines did not prevent induction 
of Fas mRNA [200]. This lack of response was also replicated in NOD islet cells treated with the NMMA 
and cytokines, with no significant change in Fas expression [179]. However, one of these studies 
reported only a small induction of Fas expression after cytokine treatment and was already at odds with 
other studies that report abundant cytokine-induced Fas expression [179]. In contrast to the above 
studies, treatment of non-human primate (NHP) islet β-cells with NMMA after incubation with cytokines 
resulted in attenuation of Fas expression. Additionally, treatment of NHP cells with the NO donor 
sodium nitroprusside (SNP) alone induced abundant Fas expression, and exposure of primary rat islets 
to cytokines after silencing iNOS expression by siRNA transfection abrogated Fas mRNA expression 
[188], and together indicate that IL-1β-induced Fas expression might at least be partly dependent on the 
presence of NO [131]. 
 This controversial involvement of NO in induction of β-cell Fas expression also appears to 
extend to its role in Fas-mediated β-cell death. There was little to no change in cell death among islets 
from wild-type as compared with iNOS-deficient mice [187], as well as amongst  mouse islets treated 
with NMMA [179, 190]. One study reported an essential role for Fas in β-cell death by showing that 





had no effect upon cell death [131]. However, although SNP alone was able to induce Fas expression in 
NHP cells, cell death was analyzed in human islets and the ability of SNP to induce Fas expression in this 
cell type had not been established. Furthermore, the link between Fas and NO would have been 
strengthened had the human islets been treated with the combination of IL-1β, SNP, and anti-Fas 
antagonist. Taken together, a majority of these studies indicate that NO is not required for induction of 
Fas expression or Fas-mediated β-cell death. Although IL-1β has been shown by multiple groups to be 
separately required for both NO and Fas expression, there appears to be no dependence for NO on Fas 
expression independent of IL-1β. 
 
Transgenic Models of T Cell-Mediated Diabetes 
 
 The TCR transgenic mouse with a rearranged TCR specific to either the CD4+ or CD8+ T cell 
population is an attractive experimental model system for study of Fas-FasL interactions in β-cell death 
for two fundamental reasons: 1) Although both leukocyte populations are already known to be required, 
the mechanisms of CD4+ and CD8+ T cell-induced diabetes can be uncoupled from each other and 
separately analyzed, with a primary focus on CD8+ CTLs due to their known role as effectors of β-cell 
death [116], and 2) Transgenic mice provide a model of diabetes that is accelerated and simplified in 
comparison to spontaneous diabetes, so that the T cell repertoire and direct β-cell death mediators can 
be studied efficiently and without the complexities that are inherent to spontaneous diabetes [154, 163, 
201, 202]. Transgenic mice can thus be used to address the autoimmune requirement and mechanism of 
cell death required for T cell-mediated disease induction, neither of which has been fully elucidated. 
 TCR transgenic β-cell death studies are unique in that most do not solely focus on Fas-FasL 
interactions as the primary death effector. As mentioned above, T cell homeostasis and CTL-mediated 
target cell death are dependent on Fas-FasL interactions in addition to other death effectors, centrally 
the perforin/granzyme pathway [22, 107, 108], and to a much lesser extent, the TNF/TNFR1 pathway 





unlike the ambiguous role for Fas-FasL interactions, perforin/granzyme appears to have a critical role in 
the effector phase of β-cell death [6, 205]. Additionally, in contrast to the initial Fas β-cell death studies 
that solely addressed Fas as a β-cell death mediator, much of Fas-relevant TCR transgenic diabetes 
research examines the role for Fas in addition to other relevant pathways in β-cell death and generally 
acknowledges that there is more than one direct mechanism involved in β-cell death. 
 One of the first studies that took this approach used transgenic mice that express β-cell-surface 
influenza virus hemagglutinin (HA), so the β-cells can be deleted by HA-specific CD8+ T cells extracted 
from TCR-transgenic mice [161]. Both the perforin and Fas pathway were separately blocked in these 
transgenic mice by use of a perforin inhibitor or by crossing the transgenic mice with the lpr/lpr 
mutation, then adoptively transferring Ins-HA recipient mice with these donor CTLs. Interestingly, loss of 
perforin alone caused a reduced incidence of diabetes, and loss of both pathways conferred a complete 
loss of diabetes induction. However, loss of Fas expression alone had a minimal impact on diabetes 
induction. Additionally, much larger numbers of perforin-deficient CTLs were required to adoptively 
transfer diabetes than Fas-deficient CTLs, and mice that received perforin-deficient CTLs still stained 
positive for small amounts of insulin amidst less islet infiltration than the mice that received Fas-
deficient CTLs. These together indicated that perforin is the major method of β-cell cytotoxicity, but in 
the absence of perforin expression, Fas-FasL interactions can cause significant cytotoxicity [161]. Two 
studies published in 2006 by the same group but using separate TCR transgenic models corroborated 
these results. Ovalbumin (OVA)-specific CTLs from OT-1 TCR transgenic mice can rapidly induce diabetes 
upon adoptive transfer to recipients that have β-cell expression of OVA and in the absence of perforin, 
β-cell killing is severely reduced. Yet absence of Fas alone has minimal effect on antigen-specific β-cell 
killing, whereas perforin- and Fas-deficiency cause complete loss of antigen-specific β-cell killing [162]. 
Islets from NOD-lpr/lpr donors were also not protected in vivo when grafted under the kidney capsule of 





cytotoxic CTLs (NOD8.3 mice) [163]. Additionally, NOD-wt islets were killed after treatment with CTLs 
from perforin-competent NOD8.3 mice, and this killing was severely reduced when the CTLS were from 
perforin-deficient NOD8.3 mice and completely abolished when NOD-lpr/lpr islets were exposed to the 
perforin-deficient CTLs [163]. Finally, treatment of 7-day-old NOD mice with an antagonist anti-FasL Ab 
after adoptive transfer of islet-specific CD8+ T lymphocytes did not inhibit diabetes or insulitis. However, 
treatment with the anti-FasL Ab after adoptive transfer of total splenocytes from diabetic mice 
conferred insulitis but not overt diabetes [151]. These results reiterate the essential role for perforin in 
CD8+ T cell-mediated β-cell death, where Fas-mediated β-cell death is still possible but likely responsible 
for insulitis and not the effector phase of β-cell death. 
 On the other hand, a separate study that also used NOD8.3 mice suggested a Fas-dependent 
mechanism of β-cell death after perforin-deficient mice actually demonstrated accelerated diabetes, 
and NOD8.3-CD8+ CTLs (either perforin-sufficient or -deficient) could kill Fas-sufficient but not Fas-
deficient lpr/lpr NOD β-cells in vitro [206]. A third study that also used the NOD8.3 experimental mouse 
model determined that perforin is required for the later stages of insulitis, whereas other perforin-
independent effector mechanisms are used in the early stages of insulitis [207]. Interestingly, although 
they used the same genetic mouse model, each of the NOD8.3 studies used CD8+ T cells that recognize 
separate β-cell peptides, making it difficult to draw conclusions from the combined study results since 
each might confer a different mechanism of action. To further complicate matters, a CD8-mediated 
transgenic model of diabetes in which mice express RIP-driven transgenes for TNF and CD80, both of 
which are required for diabetes induction, indicated a possible requirement for TNF in β-cell death, yet 
little to no role for perforin or Fas [202].  
Studies in which CD4+ T lymphocytes carry a transgenic TCR that recognizes a specific β-cell 
peptide, or CD4+-induced diabetes, are less frequently investigated than CD8+ TCR transgenic studies. 





cells in vitro, and can also express FasL upon activation [151]. Although these activated FasL+ T cells can 
kill NOD-scid/scid islets after IL-1α treatment to induce islet Fas expression, exposure to an anti-FasL Ab 
can’t decrease this death; additionally, treatment of NOD-lpr/lpr islets with the same T cell clones can be 
killed as efficiently as wild-type mice [151].  Cre-loxP is the term for a method of site-specific deletion of 
a gene of interest (in this case Fas receptor) [208], and can be driven by the RIP to confer β-cell specific 
Fas deletion (RIP-Cre+Fasfl/fl). This abrogates the lymphoid abnormalities associated with the systemic 
lpr/lpr mutation and makes it an ideal model system for generating tissue-specific deletion of a given 
molecule. Adoptive transfer of TCR-HA-CD4+ T cells into mice with a Cre-loxP Fas deletion had little 
difference in diabetes development relative to their Fas-sufficient counterparts. Furthermore, there was 
actually an accelerated rate of diabetes development in these Fas-deficient mice when induced to 
diabetes with CY [153]. Additionally, in a transgenic model of diabetes in which the T cell repertoire is 
composed of rearranged TCR genes from a CD4+ T cell clone (BDC2.5/NOD), Fas-deficient mice carrying 
the lpr/lpr mutation still developed insulitis and only a small proportion developed diabetes after 
treatment with CY [154]. Although this could be interpreted as an essential role for Fas in the 
BDC2.5/NOD mouse model, T cells transferred from BDC2.5/NOD-lpr/lpr mice to BDC2.5/NOD-wt mice 
had difficulty with proliferation; thus, like non-transgenic NOD-lpr/lpr mice, the decreased incidence of 
diabetes in BDC2.5/NOD-lpr/lpr is likely due to alterations in the T cell repertoire and not directly due to 
a Fas deficiency in the target tissue. 
In stark contrast to the above, incubation of IL-1α- and IFN-ϒ-treated NOD β-cells with a CD4+ 
clone that can differentiate into a CTL and expresses a highly diabetogenic TCR (4.1-CD4+ CTL) results in 
killing that is likely Fas-mediated, since this killing was abrogated when the islets were made Fas-
deficient by the NOD-lpr/lpr mutation [145]. In vivo, the 4.1-NOD.lpr/lpr mouse developed insulitis but 
not diabetes, unlike the wild-type NOD-lpr/lpr mouse, which develops neither insulitis nor diabetes; 





the initiation phase, whereas in the spontaneous model Fas may be responsible for the initiation phase 
of β-cell death [145]. These findings were corroborated when adoptive transfer of islet-specific CD4+ T 
cell clones (YNK7.3) into NOD mice, along with administration of an anti-FasL Ab, still conferred insulitis 
but significantly decreased diabetes incidence, yet when the recipient mice carried the lpr/lpr mutation 
insulitis was also significantly decreased [151]. In the same 4.1-NOD mouse model, another group 
showed that an IL-1R antagonist did not block induction of β-cell Fas expression, and indicates that IL-1β 
does not participate in upregulation of Fas expression in this particular diabetes model. These mice also 
appear to be capable of Fas-independent β-cell death, as demonstrated when NOD-lpr/lpr islets grafted 
into NOD4.1 mice were destroyed [147]. In contrast to these results, NOD mice infected with a 
replication-deficient adenovirus for an IL-1R antagonist protein protected the islets from activation of a 
protein known to be stimulated during Fas-mediated apoptosis after treatment of the islets with IL-1β 
and an agonist Ab for Fas. However, the possibility exists that this marker is not stimulated during 
inflammation-mediated cell death and other measures of protection from Fas-mediated cell death 
would have verified these results [146]. 
 Interestingly, one group that found little to no Fas expression on islet endocrine cells of 
spontaneously diabetic NOD mice after cytokine stimulation [179] did note Fas expression on β-cells of 
TCR transgenic models of diabetes [178]. They theorized that this contrast might be due to β-cell 
expression of certain endogenous inhibitors of Fas, such as suppressor of cytokine signaling-1 (SOCS-1) 
or an IL-1R antagonist. SOCS-1 has also received attention in some TCR transgenic mouse models due to 
this characteristic and its ability to provide a level of protection against diabetes induction by preventing 
the action of multiple cytokines via blocking the Jak-STAT signaling pathway [209] and hence, Fas cell-
surface induction. Indeed, SOCS-1 was expressed in NOD mouse islets deficient in Fas expression 
beginning at an age when they would be developing diabetes [178], and β-cell death and diabetes onset 





.NOD8.3) of CD8+-mediated diabetes [157, 163]. But this protection was perforin-dependent and Fas-
independent, as seen when NOD-lpr/lpr islets overexpressing SOCS-1 were killed by 8.3 CTLS but 
perforin-deficient islets were not [163], and when NOD4.1 mice overexpressing SOCS-1 did not show an 
induction of β-cell Fas expression yet still developed diabetes [147]. Additionally, OVA-pulsed islets from 
B6.RIP-SOCS-1 were killed by OT-1 CTLs at a comparable level to wild-type B6 islets, but perforin-
deficient OT-1 CTLs couldn’t kill the SOCS-1-protected islets [162]. These findings also corroborate the 
results from some transgenic models of CD8+-mediated diabetes, and together indicate a majorly 
perforin-dependent mechanism of β-cell death. 
  
Intracellular Pathway of Fas-Mediated β-Cell Death 
 
 Under the assumption that β-cell death is dependent upon the presence of Fas-FasL signaling, 
some groups moved to begin deducing the intracellular components required for occurrence of Fas-
mediated β-cell death. Although the intracellular pathway of Fas-mediated death has been largely 
defined in some tissues, centrally those of hematopoietic origin, available data in the context of the 
pancreatic β-cell is severely limited. Furthermore, the processes of cytokine-mediated β-cell death and 
Fas-mediated β-cell death are often uncoupled from each other under the premise that cytokines can 
mediate β-cell death directly by binding to cytokine receptors on the β-cell surface or indirectly, by 
inducing cell surface expression of death effectors such as Fas or perforin. Some studies have indicated 
separate intracellular mechanisms of death for cytokine-mediated and Fas-mediated β-cell death [210], 
which seems to be paradoxical since induction of cell-surface Fas requires β-cell exposure to cytokines. 
For the purposes of this review, however, the discussion will be limited to the intracellular components 
required for Fas-mediated β-cell death. 
 Within the rat Fas promoter, an IL-1β-responsive region was determined to be between 
nucleotides -223 and -54 [211]. The transcription factors nuclear factor kappa-light-chain-enhancer of 





responsive sequence at nucleotide -142 and -130 respectively, and both were determined to be critical 
to the Fas IL-1β response, as mutation of either alone causes a loss in expression normally induced by IL-
1β [211].  
The responsiveness of the Fas promoter to IL-1β ultimately results in cell surface induction of 
Fas receptor. As reviewed above (Figure 2), subsequent association of the FADD adaptor protein 
precedes oligomerization and activation of caspase-8. Indeed, this progression also occurs in the β-cell, 
where a β-cell-specific dominant-negative FADD (RIP-dnFADD) lacks a death effector domain and 
competitively inhibits binding of endogenous FADD to the death domain of Fas, which would ultimately 
prevent activation of the downstream components in this death pathway [148]. In vitro treatment of 
NOD-RIP-dnFADD islet cells with IL-1β + IFN-ϒ + FasL conferred resistance to cell death, whereas wild-
type controls were sensitive to cell death after these treatments. Additionally, diabetes incidence of 
homozygous RIP-dnFADD mice was slightly reduced as compared with NOD-wt control mice, and 
indicates a role, albeit minor, for Fas-FasL signaling in β-cell death [148]. These results also were 
corroborated in vitro, whereby blocking FADD activity in NIT-1 cells leads to a significant but not 
complete protection from cell lysis [212]. 
Just downstream of the FADD, initiator caspase-8 activity also appears to be required; however, 
evidence for the critical role of caspase-8 in Fas-mediated β-cell death is derived from islets of human 
Type 2 diabetic islets, so should be cautiously translated to the Type 1 diabetic circumstance. As 
indicated above, in vitro islet exposure to glucose can induce Fas cell surface expression [184]. FLICE-like 
inhibitory protein (FLIP), an endogenous protein that competitively inhibits caspase-8 by its structural 
similarity and lack of proteolytic activity, has decreased protein expression levels within islets from Type 
2 diabetics relative to healthy controls. This decrease in FLIP after in vitro glucose exposure also has an 





decreases [213]. Although not directly measured in the study, these data and correlations could indicate 
an essential role for caspase-8 in Fas β-cell signaling.  
The intrinsic mitochondrial pathway appears not to be necessary in inflammation-mediated β-
cell death; although required in vitro for Fas-mediated mouse islet cell death [50], NOD mice deficient in 
Bid were not protected from development of spontaneous diabetes in vivo [149]. Finally, the effector 
caspase-3 has been investigated by multiple groups for its potential role in Fas-dependent β-cell death. 
βTC1 insulinoma cells that were transfected with human Fas cDNA (hFas/βTC1) and exposed to an 
agonist anti-Fas Ab had a marked increase in caspase-3-like activity. hFas/βTC1 cells transfected with an 
anti-sense knockout of caspase-3 and then treated with agonist anti-Fas also had increased survival over 
control hFas/βTC1 cells that lacked the caspase-3 knockout [214].  Additionally, NIT-1 insulinoma cells 
treated with IL-1β + IFN-γ + FasL showed an increase in caspase-3 like activity, as compared with NIT-1 
cells treated with cytokines alone [197, 215]. Finally, βLox5 is one of few available cell lines that is 
derived from adult human β-cells. When these IL-1β-resistant cells are made deficient in mitochondrial 
DNA, they are still sensitive to Fas-mediated killing, which is blocked upon addition of a pan-caspase 
inhibitor to the treatment. Although there was no negative control for comparison, these data indicate 
that in the absence of the mitochondrial pathway, Fas-mediated β-cell death can proceed in a caspase-
dependent manner [210]. Although the above-mentioned elements appear to be critical for the effector 
function of β-cell Fas-FasL interactions, it is still unclear if Fas plays a role in any stage of β-cell death. 
 
 IV. Effect of Fas Signaling on Healthy β-Cell Function 
A large proportion of Fas literature investigates its role in AICD and a growing body of studies 
analyzes its role in pathogenic β-cell death, which together and in addition to others characterizes Fas-
FasL signaling as a mostly pro-death event. However, Fas-FasL interactions can promote survival, 





groups in particular analyzed the role of Fas in both healthy and pathological β-cell function by use of 
the Cre-loxP Fas deletion model [150, 155]. Schumann et al. crossed the RIP-Cre+Fasfl/fl deletion into mice 
of the NOD.C57BL/6j background and reported a surprising finding in that absence of Fas signaling 
impaired glucose tolerance and lowered insulin levels. They speculated on a role for Fas in β-cell 
secretory function [150]. This investigation was conducted by the same group that earlier published a 
study characterizing a dual role for Fas signaling in the β-cell; Fas β-cell expression was previously shown 
to be induced by glucose [184], which also directs expression of the caspase-8 inhibitor FLIP [213]. A 
dual role for Fas was proposed in the latter study, where increased FLIP expression promoted Fas-
mediated proliferation and decreased FLIP expression caused Fas signaling to promote cell death, all of 
which were dependent on islet exposure to high concentrations of glucose [213]; aging was also 
correlated with enhanced death in cells exposed to high glucose concentration [192]. These were 
followed up by Schumann et al., who showed that transfection of INS-1E insulinoma cells or mouse islets 
with FLIP promoted mRNA expression of pro-survival factors, such as PDX-1, insulin, and NF-ĸB; while 
Fas separately caused similar effects in this study, the dependence on Fas for the FLIP phenotype was 
not directly measured [150].  
Another group, using the RIP-Cre+Fasfl/fl mice of the 129J-C57BL/6 genetic background, reported 
opposing findings in that these mice had higher glucose tolerance and GSIS than their wild-type 
counterparts, although both wild-type and RIP-Cre+Fasfl/fl mice had similar insulin content and total 
pancreatic content [155]. Absence of Fas signaling promoted β-cell function and Fas was not required 
for islet β-cell development, as has also been suggested by other groups [148]. Moreover, there was no 
change in incidence of multiple low-dose streptozotocin (MLDS)-induced diabetes between wild-type 
and RIP-Cre+Fasfl/fl mice, indicating that Fas-FasL signaling is not critical to MLDS-induced autoimmune 
diabetes [155]. Choi et al. theorized that this disparity might result from the separate genetic 





diabetes induction was different in each of these studies, where Schumann et al. used mice of the 
NOD.C57BL/6j background and Choi et al. induced T1DM with MLDS; however, the separate methods of 
diabetes induction still wouldn’t explain the disparity between the studies in secretory function.  
 
V. Transgenic FasL as a Means of β-Cell Protection  
 Whereas some groups have attempted to characterize a role for Fas-FasL interactions in β-cell 
pathology, others have taken a different approach by attempting to determine if Fas-FasL can confer β-
cell protection by deletion of autoreactive Fas-expressing immune cells. Although the ability of islet β-
cells to express FasL remains controversial [131, 171, 176, 179, 180, 185], its well-characterized role in 
maintaining immune privilege of some tissues [67, 68] encouraged experimentation with ectopically 
expressed β-cell FasL to render the β-cell an immune-privileged site and protect it from autoimmune 
destruction. Its requirement for corneal graft survival [70] also indicated FasL as a therapeutic target for 
successful transplantation of organ and islet allografts. Furthermore, the possibility that animals 
transgenic for FasL could essentially have an endogenous means of immunosuppression at sites that do 
not naturally confer immune privilege was extraordinarily appealing [217]. However, FasL 
overexpression also presents the risk of inducing cell death in any Fas-expressing cell located within 
proximity of ectopic FasL. 
 Indeed, experimentation with mice transgenic for FasL, however, did not yield the expected 
protective outcome. NOD mice that express FasL under control of either the human insulin promoter 
(HIP) or RIP, conferring β-cell-specific gene expression, developed diabetes at an accelerated rate as 
compared with their nontransgenic littermates [25, 139, 218, 219], and the rate of acceleration between 
transgenic strains was dependent upon the baseline level of FasL expression [25, 220]. Corroborating 
well with these findings, C57BL/6 mice transgenic for human FasL (hFasL) and induced to diabetes with 





Ectopic FasL-driven accelerated disease development was particularly evident amongst 
transgenic NOD males, which develop spontaneous diabetes at a more delayed rate than female NOD 
mice, but develop accelerated diabetes at a similar rate as transgenic females. This diabetes acceleration 
was abolished, however, with addition of the dominant-negative lprᶜᵍ transgene. RIP-FasL- lprᶜᵍ mice 
developed spontaneous diabetes at a slightly decreased rate relative to NOD-wt mice, but after adoptive 
transfer of diabetogenic splenocytes into NOD-RIP-FasL mice, introduction of the lprᶜᵍ mutation was only 
able to reduce diabetes incidence to levels comparable to that of wild-type mice [139], and also 
indicates that Fas-independent mechanisms are employed in the adoptive transfer model of diabetes 
induction. Additionally, HIP-FasL mice of a non-diabetes-prone genetic background did not develop the 
accelerated spontaneous diabetes seen in NOD mice [218]. This indicates that the NOD, or diabetes-
prone-background, is required for the accelerated diabetes caused by ectopic FasL expression; without 
chemically-induced or immune-mediated islet inflammation, Fas has no way of being induced to the β-
cell surface and thus ligating FasL to initiate cell death. Finally, mice virally induced to develop T1DM by 
β-cell-specific expression of the nucleoprotein of lymphocytic choriomeningitis virus (RIP-LCMV) and 
carrying ectopic FasL (RIP-FasL) had a significant reduction in diabetes as compared to their non-RIP-FasL 
littermates [221]. Although this turned out to be due to FasL-mediated killing of autoreactive CD8+ 
lymphocytes, RIP-FasL mice infected with LCMV but lacking the nucleoprotein still developed diabetes. 
Significantly, the LCMV virus induced β-cell Fas expression; thus, this diabetes was caused by β-cell 
fratricide and exemplifies the central problem inherent to ectopically expressed β-cell FasL. 
      Accelerated rejection was also demonstrated amongst islets that were grafted from 
transgenic donor mice and transplanted under the renal capsule of recipient mice, an outcome that 
could be attained with either mFasL or sFasL [222]. In this scenario, FasL islet expression was driven by 
either the rat insulin promoter or a replication-deficient adenoviral vector containing FasL cDNA 





vector lacking FasL cDNA, RIP-FasL or AdFasL islets were rapidly infiltrated and destroyed [220, 223, 
224]. To corroborate these findings, diabetic NOD recipient mice transplanted under the kidney capsule 
with syngeneic islets maintained normoglycemia for 7-14 days, whereas treatment with a neutralizing 
anti-FasL Ab extended this period to 30 days [158]. In addition, administration of a neutralizing anti-Fas 
Ab to female NOD mice at 2-4 weeks of age almost completely prevented spontaneous diabetes onset 
and delayed its incidence when administered at 5-15 weeks old [151]. However, protection from 
accelerated islet rejection could be attained when the islets were co-transplanted with FasL-expressing 
myoblasts or testicular allografts, which may allow for continued interest in FasL as means of protection 
for islet transplantation [225, 226]. 
Interestingly, AdFasL islets from MRL-lpr/lpr mice and their Fas-sufficient counterparts were 
rejected in the same amount of time, which would suggest that FasL-expressing islets are not killed by 
autocrine interaction between islet Fas and FasL [224]. In vitro, however, treatment of RIP-FasL islets 
with IL-1β and IFN-γ resulted in an almost three-fold increase in cell death as compared with 
nontransgenic islets and was prevented by treatment with an antagonist anti-FasL Ab, which would 
suggest that cytokines upregulate β-cell Fas, hence making the cell susceptible to autocrine Fas-FasL 
interaction [219, 223]. These discrepant results could be rationalized by a different mechanism of action 
between RIP-FasL and AdFasL islets, but has not been conclusively determined. Finally, the genetic 
background of both donor and recipient mouse appears to plays a critical role in determination of 
whether an islet transplant will be successful or rejected. Whereas syngeneic grafts from nontransgenic 
C57BL/6 mouse donors had very little islet graft infiltration, grafts from RIP-FasL mice had undergone 
infiltration and some had already been rejected. In contrast, allogeneic grafts from both nontransgenic 
and transgenic hosts were rejected [220], and indicates that the donor and recipient must be genetically 
identical for successful graft transplantation but that, contrary to contributing to transplant success, islet 





The findings in transgenic mice and FasL-expressing islet grafts bring into question the 
difference in mechanism between naturally expressed ectopic FasL and transgenic FasL and why they 
confer such different outcomes. FasL islet expression appears to not only provoke acceleration of 
diabetes, but also is not an appropriate therapeutic target for islet grafting. Based on the herein 
reported results, mice transgenic for β-cell FasL may be susceptible to autocrine Fas-FasL interaction 
after FasL-mediated neutrophil recruitment and subsequent Fas β-cell-surface activity.  
In opposition to transgenic β-cell Fas expression, silencing of Fas expression by siRNA technology 
may be a potential route to therapy. NOD mice were significantly protected from CY-induced diabetes 
when a systemic non-viral Fas siRNA was administered intravenously at the time of CY administration, 
but it is not known if these mice also carried the abnormal phenotype conferred by the lpr/lpr Fas 
deficiency mutation. The potential role for Fas in insulitis was reiterated when Fas siRNA was 
administered to these mice during the β-cell death phase of CY-induced diabetes, where there was no 
protection from diabetes [227]. This also indicates that therapies against Fas-FasL interactions might be 





 Fas-FasL signaling is fundamental to maintenance of homeostasis in multiple tissues.  Binding of 
FasL to its receptor is characterized by autocrine or paracrine interaction, of which is largely determined 
by the ability of the tissue in question to express the receptor, ligand, or both [8]. Any tissue that can 
express cell surface Fas is vulnerable to death by ligation of FasL, and FasL expression is therefore strictly 
limited to activated T and NK cells, in addition to its constitutive expression on tissues of immune 
privilege. However, this concept of FasL-mediated immune privilege appears to be limited to specific 





development, in stark contrast to the intended purpose of protection from autoimmune invasion [25, 
139, 218, 219]. 
Perhaps the most critical role for Fas signaling is in peripheral selection and maintenance of 
immune homeostasis, as was revealed by the abnormal hematopoietic cell repertoire in mice with a 
systemic deficiency of Fas (lpr/lpr) or FasL (gld/gld). These mice exhibited a number of abnormal 
phenotypes, such as massive lymphoproliferation and accumulation of non-malignant double-negative T 
cells in the spleen and lymph nodes. Following these findings, investigation into the role for Fas signaling 
in β-cell death was sparked with the demonstration that mice carrying the lpr/lpr and gld/gld mutations 
were completely protected from autoimmune diabetes development [24, 25, 138] and NOD-lpr/lpr mice 
adoptively transferred with diabetogenic cells failed to develop diabetes, which together cast a critical 
role for Fas signaling in β-cell death. However, it was soon realized that this protection from diabetes did 
not result from absence of Fas signaling on the β-cell, but rather as a result of the lymphoid 
abnormalities conferred by absence of Fas on the hematopoietic cell surface, and prevented the 
autoimmune response required for T1DM initiation. NOD-lpr/lpr mice also express high levels of FasL, 
which was likely killing adoptively transferred splenocytes before they could initiate diabetes in the 
recipient mouse [137, 140]. Although Fas β-cell studies using only the systemic lpr/lpr or gld/gld 
mutation are not applicable to determining its role in β-cell pathology, interest in Fas as a β-cell death 
effector lingered with the demonstration that pro-inflammatory cytokines, namely IL-1β, induced mRNA 
and cell-surface β-cell Fas expression [23] and that β-cells isolated from newly-diagnosed diabetes 
patients had abundant β-cell-surface Fas expression [131, 171]. However, the multiple genetic 
backgrounds comprising the in vivo and in vitro Fas β-cell death research, in combination with numerous 






 There exists a broad repertoire of studies that have concluded some role for Fas signaling in β-
cell death. Although the extent of its role varies between studies, there seems to be a general consensus 
that more than one death effector participate in β-cell death, and confers both Fas-dependent and Fas-
independent mechanisms of death. For example, sublethally irradiated NOD-scid/scid-lpr/lpr mice 
reconstituted with diabetogenic spleen cells had a significant reduction in diabetes incidence relative to 
NOD-scid/scid counterparts that were sufficient in Fas; this suggests a Fas-dependent mechanism of 
disease development. However, a level of disease development still occurred in the Fas-deficient mice, 
which also suggests Fas-independent T1DM development [138, 139]. TCR transgenic mouse with a 
rearranged TCR specific to the CD8+ T cell population, conferring CD8+-mediated diabetes, found that 
the perforin/granzyme signaling pathway comprises the major effector in β-cell death, but in the 
absence of perforin, Fas signaling is also capable of executing β-cell death [161-163]. Also in CD8+ and 
one model of CD4+ transgenic mice, there were reports that the Fas signaling pathway is responsible for 
the initiation phase of β-cell death, whereas the perforin/granzyme pathway is responsible for the 
effector phase [145, 151]. Furthermore, one of the first studies that analyzed the contribution of 
perforin/granzyme to β-cell death found that perforin-deficient mice developed insulitis but not overt 
diabetes, supporting this role for Fas in the initiation phase of diabetes development [6]. These findings 
were also maintained by a study in which female NOD mice administered with a neutralizing anti-Fas Ab 
at 2-4 weeks old were almost completely protected from spontaneous diabetes, and when administered 
at 5-15 weeks they had a delayed incidence. In contrast, when the neutralizing Ab was administered at a 
later time when β-cell death was occurring, diabetes incidence was unaffected [151]. Together, these 
findings strongly suggest that the perforin/granzyme signaling pathway comprises the effector phase of 
β-cell death, and that Fas signaling is likely responsible for the initiation phase of this process. 
 Contrary to the above, however, a significant proportion of Fas β-cell research has indicated that 





gld/gld mice reconstituted with wild-type splenocytes did not develop diabetes even though the 
recipients were Fas-sufficient and the adoptively transferred splenocytes were FasL-sufficient [141]. 
NOD mice deficient in IL-1β and thus unable to induce Fas to the β-cell surface also did not have 
decreased diabetes incidence relative to NOD-wt littermates [144]. Further, an in vitro model of 
transgenic CD4+-induced diabetes revealed that treatment of NOD-lpr/lpr islets with the CD4+ T cell 
clones elicited a similar killing efficiency as NOD-wt islets [151]. β-cell-specific deletion of Fas gene (RIP-
Cre+Fasfl/fl) on the 129J-C57BL/6 mouse genetic background did not confer any protection from diabetes 
induced with MLDS relative to their Fas-sufficient counterparts [155]. These more recent results from a 
highly tissue-specific model diminish the likelihood of a critical role for Fas signaling during autoimmune-
mediated β-cell death. Moreover, diabetes incidence was not affected upon injection of a neutralizing 
anti-FasL Ab after disease induction with either CY or adoptive transfer of diabetogenic splenocytes 
[152]. It does, however, bear mention that blocking the Fas pathway in the early stages of CY-triggered 
diabetes prevents diabetes incidence [143], not by blocking Fas β-cell signaling, but likely by preventing 
the T cell deletion that CY should confer [152, 228].  
 Nevertheless, Fas might still play a critical role in development of T1DM, not through its 
signaling in β-cells but from its altered signaling in the hematopoietic cellular population, which could 
result in dysfunctional AICD of autoreactive T lymphocytes localized to the pancreatic islet [229]. Indeed, 
newly-diagnosed diabetes patients have significantly decreased Fas expression on the surface of T and B 
cells relative to healthy controls [230] and T lymphocytes from NOD mice have demonstrated a 
resistance to AICD [231]. Also in support of this idea, treatment of NOD mice with an agonist anti-Fas Ab 
conferred resistance to diabetes; immunohistochemical analysis of pancreatic samples from these 
animals showed that infiltrating cells and not insulin-positive cells were being targeted by the Ab (data 
not shown)[182], although how the antibody selectively targeted hematopoietic cells and not endocrine 





fusion protein of FasL bound to streptavidin (conferring an effective ability to induce cell death in 
diabetogenic cells) into NOD female mice resulted in a significantly delayed incidence of diabetes [160]. 
Similar results were also demonstrated in mice injected with an AdCTLA4-FasL fusion protein, when the 
mice were induced with MLDS and failed to develop diabetes; additionally, splenocytes from these mice 
could not induce diabetes in syngeneic recipients [156]. Taken together, targeting the autoreactive T cell 
repertoire by administration of an agonist Ab for Fas or soluble Fas ligand might be an effective 
therapeutic intervention. However, the treatment would have to be specific for the target population, as 
any cell that constitutively expresses Fas would be otherwise vulnerable to death, potentially resulting in 
severe side effects and even death [40, 81].  
  Islet β-cell death studies are conducted in a wide variety of in vivo and in vitro models that 
together comprise a number of genetic backgrounds, some of which are described above for 
investigation of Fas-FasL signaling in β-cell death and development of T1DM. This range of model 
systems can confer separate mechanisms of general function and death, as has been illustrated in the 
numerous Fas β-cell death studies that are unable to come to a consensus on the role for Fas signaling in 
β-cell death and T1DM development. Ultimately, the use of one single and appropriate model system 
would likely diminish this disparity in reported findings. A possibility of such is the Cre-loxP 
recombination system, whereby Fas is the target gene and Cre recombinase expression is driven by the 
RIP to confer β-cell-specific gene deletion; this would present a simple and effective model system for 
use in Fas β-cell research. Two groups have already used Cre-loxP gene targeting to analyze the role for 
Fas in insulin secretion (NOD genetic background) [150] and β-cell pathology (non-NOD genetic 
background) [155], but reported contrasting findings. Investigators have yet to explore β-cell pathology 
using Cre-loxP gene targeting on the NOD mouse background, which would confer β-cell-specific Fas 
deletion in a mouse model of spontaneous diabetes. This type of study design holds promise for the 





Finally, although the NOD mouse is an extraordinarily useful model for the study of T1DM, it 
likely has a separate mechanism of β-cell death relative to humans; this is exemplified by the numerous 
cures identified in the NOD mouse, of which are yet to be successfully translated to a human T1DM 
patient [232]. Use of human islets for such studies may be the preferred genetic model for two 
fundamental reasons: 1) Use of one genetic model for all T1DM studies might eliminate the disparity 
between studies, and 2) Results from human islet studies are more likely to translate to a living human. 
However, human pancreatic biopsy sampling is exceptionally difficult and costly due to the inaccessible 
physiology of the pancreas. Although research into the mechanism underlying β-cell death has 
progressed significantly in recent years, an ideal model system has yet to be developed that can 





















































1. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB: Metabolic cycling 
in control of glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2008, 
295(6):E1287-1297. 
2. Cheng D: Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 
2005, 2:29. 
3. Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during progression to 
diabetes. Diabetes 2004, 53 Suppl 3:S16-21. 
4. Yessoufou A, Moutairou K: Maternal diabetes in pregnancy: early and long-term outcomes on 
the offspring and the concept of "metabolic memory". Exp Diabetes Res 2011, 2011:218598. 
5. Rathmell JC, Goodnow CC: Autoimmunity. The Fas track. Curr Biol 1995, 5(11):1218-1221. 
6. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H: Reduced incidence and 
delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997, 
186(7):989-997. 
7. Kagi D, Ho A, Odermatt B, Zakarian A, Ohashi PS, Mak TW: TNF receptor 1-dependent beta cell 
toxicity as an effector pathway in autoimmune diabetes. J Immunol 1999, 162(8):4598-4605. 
8. Nagata S, Golstein P: The Fas death factor. Science 1995, 267(5203):1449-1456. 
9. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK: Immunopathology of the human 
pancreas in type-I diabetes. Semin Immunopathol 2011, 33(1):9-21. 
10. Cooke DW, Plotnick L: Type 1 diabetes mellitus in pediatrics. Pediatr Rev 2008, 29(11):374-384; 
quiz 385. 
11. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA: Pancreatic Extracts in the Treatment 
of Diabetes Mellitus. Can Med Assoc J 1922, 12(3):141-146. 
12. Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, 
Wentholt IM, Hoekstra JB et al: Sensor-augmented pump therapy lowers HbA(1c) in 
suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 2011, 
28(10):1158-1167. 
13. van Belle TL, Coppieters KT, von Herrath MG: Type 1 diabetes: etiology, immunology, and 
therapeutic strategies. Physiol Rev 2011, 91(1):79-118. 
14. Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, Nierras CR, Todd JA, Rich SS, 
Nerup J: Genetics of type 1 diabetes: what's next? Diabetes 2010, 59(7):1561-1571. 
15. Bonifacio E, Ziegler AG: Advances in the prediction and natural history of type 1 diabetes. 
Endocrinol Metab Clin North Am 2010, 39(3):513-525. 
16. Bluestone JA, Herold K, Eisenbarth G: Genetics, pathogenesis and clinical interventions in type 
1 diabetes. Nature 2010, 464(7293):1293-1300. 
17. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and 
treatment. Lancet 2001, 358(9277):221-229. 
18. Burke GW, 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A: Recurrence of 
autoimmunity following pancreas transplantation. Curr Diab Rep 2011, 11(5):413-419. 
19. Collier JJ, Fueger PT, Hohmeier HE, Newgard CB: Pro- and antiapoptotic proteins regulate 
apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell 
lines. Diabetes 2006, 55(5):1398-1406. 
20. Collier JJ, Burke SJ, Eisenhauer ME, Lu D, Sapp RC, Frydman CJ, Campagna SR: Pancreatic beta-
cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS 
One 2011, 6(7):e22485. 
21. Steer SA, Scarim AL, Chambers KT, Corbett JA: Interleukin-1 stimulates beta-cell necrosis and 





22. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas 
and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 
265(5171):528-530. 
23. Stassi G, Todaro M, Richiusa P, Giordano M, Mattina A, Sbriglia MS, Lo Monte A, Buscemi G, 
Galluzzo A, Giordano C: Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human beta-
cells sorted by flow-cytometry and cultured in vitro. Transplant Proc 1995, 27(6):3271-3275. 
24. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, Moriwaki M, Nakajima H, 
Miyagawa J, Namba M et al: Requirement of Fas for the development of autoimmune diabetes 
in nonobese diabetic mice. J Exp Med 1997, 186(4):613-618. 
25. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA, Jr., Matis LA: The role of 
Fas in autoimmune diabetes. Cell 1997, 89(1):17-24. 
26. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, 
Trauth BC et al: Purification and molecular cloning of the APO-1 cell surface antigen, a member 
of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity 
with the Fas antigen. J Biol Chem 1992, 267(15):10709-10715. 
27. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface 
antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 
169(5):1747-1756. 
28. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S: 
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate 
apoptosis. Cell 1991, 66(2):233-243. 
29. Inazawa J, Itoh N, Abe T, Nagata S: Assignment of the human Fas antigen gene (Fas) to 10q24.1. 
Genomics 1992, 14(3):821-822. 
30. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The 
cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J 
Immunol 1992, 148(4):1274-1279. 
31. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH: The human APO-1 (APT) antigen maps 
to 10q23, a region that is syntenic with mouse chromosome 19. Genomics 1992, 14(1):179-180. 
32. Krammer PH: CD95's deadly mission in the immune system. Nature 2000, 407(6805):789-795. 
33. Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human 
Fas antigen. J Biol Chem 1993, 268(15):10932-10937. 
34. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW: NMR structure and mutagenesis 
of the Fas (APO-1/CD95) death domain. Nature 1996, 384(6610):638-641. 
35. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a 
novel member of the tumor necrosis factor family. Cell 1993, 75(6):1169-1178. 
36. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J 
Exp Med 1994, 179(3):873-879. 
37. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas ligand: gene structure, 
chromosomal location and species specificity. Int Immunol 1994, 6(10):1567-1574. 
38. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized 
lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 
76(6):969-976. 
39. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human 
fas ligand in activated lymphocytes. EMBO J 1995, 14(6):1129-1135. 
40. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S: Lethal effect of recombinant human Fas 
ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997, 158(5):2303-2309. 
41. Strasser A, Jost PJ, Nagata S: The many roles of FAS receptor signaling in the immune system. 





42. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nat Med 1998, 
4(1):31-36. 
43. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J: Conversion of 
membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its 
proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187(8):1205-1213. 
44. LA OR, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT 
et al: Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 
461(7264):659-663. 
45. Hohlbaum AM, Moe S, Marshak-Rothstein A: Opposing effects of transmembrane and soluble 
Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000, 191(7):1209-
1220. 
46. Lavrik IN, Krammer PH: Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 2012, 
19(1):36-41. 
47. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter 
ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17(6):1675-1687. 
48. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S: Bcl-2 and Fas/APO-1 regulate distinct 
pathways to lymphocyte apoptosis. EMBO J 1995, 14(24):6136-6147. 
49. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ: Bid-deficient mice 
are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400(6747):886-891. 
50. McKenzie MD, Carrington EM, Kaufmann T, Strasser A, Huang DC, Kay TW, Allison J, Thomas HE: 
Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of 
pancreatic beta-cells. Diabetes 2008, 57(5):1284-1292. 
51. Eckelman BP, Salvesen GS, Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the 
black sheep of the family. EMBO Rep 2006, 7(10):988-994. 
52. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner 
C, Silke J et al: XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 
2009, 460(7258):1035-1039. 
53. Kaufmann T, Strasser A, Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death 
Differ 2012, 19(1):42-50. 
54. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in 
the Fas pathway of apoptosis. Cell 1998, 94(4):491-501. 
55. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a Bcl2 interacting protein, mediates 
cytochrome c release from mitochondria in response to activation of cell surface death 
receptors. Cell 1998, 94(4):481-490. 
56. Zaltsman Y, Shachnai L, Yivgi-Ohana N, Schwarz M, Maryanovich M, Houtkooper RH, Vaz FM, De 
Leonardis F, Fiermonte G, Palmieri F et al: MTCH2/MIMP is a major facilitator of tBID 
recruitment to mitochondria. Nat Cell Biol 2010, 12(6):553-562. 
57. Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that promotes cytochrome c-
dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102(1):33-42. 
58. Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional 
apoptosome that activates procaspase-9. J Biol Chem 1999, 274(17):11549-11556. 
59. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, 
Tschopp J, Wajant H et al: The CD95 receptor: apoptosis revisited. Cell 2007, 129(3):447-450. 
60. Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, Krammer PH, Lavrik IN, Eils R: Dynamics 






61. Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH: Analysis of CD95 threshold signaling: 
triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J 
Biol Chem 2007, 282(18):13664-13671. 
62. Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, Hirt UA, Walczak H, Falk W, 
Essig M et al: Neutralization of CD95 ligand promotes regeneration and functional recovery 
after spinal cord injury. Nat Med 2004, 10(4):389-395. 
63. Drappa J, Brot N, Elkon KB: The Fas protein is expressed at high levels on CD4+CD8+ 
thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone 
strain, MRL lpr/lpr. Proc Natl Acad Sci U S A 1993, 90(21):10340-10344. 
64. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N: Differential expression 
of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J 
Immunol 1992, 149(11):3753-3758. 
65. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas 
ligand in cells of T cell lineage. J Immunol 1995, 154(8):3806-3813. 
66. Green DR, Ferguson TA: The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001, 
2(12):917-924. 
67. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a 
mechanism of immune privilege. Science 1995, 270(5239):1189-1192. 
68. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in 
preventing graft rejection. Nature 1995, 377(6550):630-632. 
69. Ferguson TA, Griffith TS: A vision of cell death: Fas ligand and immune privilege 10 years later. 
Immunol Rev 2006, 213:228-238. 
70. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA: CD95 ligand (FasL)-induced 
apoptosis is necessary for corneal allograft survival. J Clin Invest 1997, 99(3):396-402. 
71. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer 
PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor 
cells--a mechanism of immune evasion? Nat Med 1996, 2(12):1361-1366. 
72. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: cancer 
as a site of immune privilege. Immunol Today 1999, 20(1):46-52. 
73. Ryan AE, Shanahan F, O'Connell J, Houston AM: Addressing the "Fas counterattack" 
controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer 
in vivo. Cancer Res 2005, 65(21):9817-9823. 
74. Igney FH, Krammer PH: Tumor counterattack: fact or fiction? Cancer Immunol Immunother 
2005, 54(11):1127-1136. 
75. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, 
Ware CF et al: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced 
apoptosis in T-cell hybridomas. Nature 1995, 373(6513):441-444. 
76. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by 
APO-1/(Fas/CD95). Nature 1995, 373(6513):438-441. 
77. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: 
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 
1995, 373(6513):444-448. 
78. Bosselut R: CD4/CD8-lineage differentiation in the thymus: from nuclear effectors to 
membrane signals. Nat Rev Immunol 2004, 4(7):529-540. 
79. Labrecque N, Baldwin T, Lesage S: Molecular and genetic parameters defining T-cell clonal 
selection. Immunol Cell Biol 2011, 89(1):16-26. 






81. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, 
Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364(6440):806-
809. 
82. Starr TK, Jameson SC, Hogquist KA: Positive and negative selection of T cells. Annu Rev Immunol 
2003, 21:139-176. 
83. MacDonald HR, Radtke F, Wilson A: T cell fate specification and alphabeta/gammadelta lineage 
commitment. Curr Opin Immunol 2001, 13(2):219-224. 
84. Palmer E: Negative selection--clearing out the bad apples from the T-cell repertoire. Nat Rev 
Immunol 2003, 3(5):383-391. 
85. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas 
antibody. J Exp Med 1995, 181(2):485-491. 
86. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H, Ogasawara J, Tanaka T, Yoshida N, 
Nagata S: Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci U 
S A 1996, 93(5):2131-2136. 
87. Singer GG, Abbas AK: The fas antigen is involved in peripheral but not thymic deletion of T 
lymphocytes in T cell receptor transgenic mice. Immunity 1994, 1(5):365-371. 
88. Watanabe T, Sakai Y, Miyawaki S, Shimizu A, Koiwai O, Ohno K: A molecular genetic linkage map 
of mouse chromosome 19, including the lpr, Ly-44, and Tdt genes. Biochem Genet 1991, 29(7-
8):325-335. 
89. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, Matsuzawa A, Rochelle JM, 
Seldin MF: Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease 
manifestations and renal disease-modifying loci. J Exp Med 1992, 176(6):1645-1656. 
90. Roths JB, Murphy ED, Eicher EM: A new mutation, gld, that produces lymphoproliferation and 
autoimmunity in C3H/HeJ mice. J Exp Med 1984, 159(1):1-20. 
91. Allen RD, Marshall JD, Roths JB, Sidman CL: Differences defined by bone marrow 
transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of 
molecules. J Exp Med 1990, 172(5):1367-1375. 
92. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation 
disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 
356(6367):314-317. 
93. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of 
an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad 
Sci U S A 1993, 90(5):1756-1760. 
94. Nagata S: Mutations in the Fas antigen gene in lpr mice. Semin Immunol 1994, 6(1):3-8. 
95. Watanabe D, Suda T, Hashimoto H, Nagata S: Constitutive activation of the Fas ligand gene in 
mouse lymphoproliferative disorders. EMBO J 1995, 14(1):12-18. 
96. Matsuzawa A, Moriyama T, Kaneko T, Tanaka M, Kimura M, Ikeda H, Katagiri T: A new allele of 
the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the 
mouse. J Exp Med 1990, 171(2):519-531. 
97. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16(1):39-43. 
98. Karray S, Kress C, Cuvellier S, Hue-Beauvais C, Damotte D, Babinet C, Levi-Strauss M: Complete 
loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a 
residual activity of gld allele. J Immunol 2004, 172(4):2118-2125. 
99. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and 
lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269. 
100. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED: Induction of various 





101. Perry D, Sang A, Yin Y, Zheng YY, Morel L: Murine models of systemic lupus erythematosus. J 
Biomed Biotechnol 2011, 2011:271694. 
102. Turbyville JC, Rao VK: The autoimmune lymphoproliferative syndrome: A rare disorder 
providing clues about normal tolerance. Autoimmun Rev 2010, 9(7):488-493. 
103. Owen-Schaub LB, Yonehara S, Crump WL, 3rd, Grimm EA: DNA fragmentation and cell death is 
selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell 
Immunol 1992, 140(1):197-205. 
104. Russell JH, Rush B, Weaver C, Wang R: Mature T cells of autoimmune lpr/lpr mice have a defect 
in antigen-stimulated suicide. Proc Natl Acad Sci U S A 1993, 90(10):4409-4413. 
105. Lynch DH, Alderson MR, Ramsdell F: Immunoregulatory effects of Fas-mediated signalling. J 
Cell Biochem 1996, 60(1):39-46. 
106. Wu J, Zhou T, Zhang J, He J, Gause WC, Mountz JD: Correction of accelerated autoimmune 
disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in 
the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci U S A 1994, 91(6):2344-2348. 
107. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, 
Yagita H, Okumura K et al: Two distinct pathways of specific killing revealed by perforin mutant 
cytotoxic T lymphocytes. Immunity 1994, 1(5):357-364. 
108. Lowin B, Beermann F, Schmidt A, Tschopp J: A null mutation in the perforin gene impairs 
cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 
1994, 91(24):11571-11575. 
109. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR: Uptake of apoptotic 
antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce 
active immune unresponsiveness. J Immunol 2002, 168(11):5589-5595. 
110. Bossi G, Griffiths GM: Degranulation plays an essential part in regulating cell surface 
expression of Fas ligand in T cells and natural killer cells. Nat Med 1999, 5(1):90-96. 
111. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P: TCR/CD3 coupling to Fas-
based cytotoxicity. J Exp Med 1995, 181(2):781-786. 
112. Arnold R, Brenner D, Becker M, Frey CR, Krammer PH: How T lymphocytes switch between life 
and death. Eur J Immunol 2006, 36(7):1654-1658. 
113. Mizuno T, Zhong X, Rothstein TL: Fas-induced apoptosis in B cells. Apoptosis 2003, 8(5):451-460. 
114. Daniel PT, Krammer PH: Activation induces sensitivity toward APO-1 (CD95)-mediated 
apoptosis in human B cells. J Immunol 1994, 152(12):5624-5632. 
115. Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton RA, Hartig H, 
Sundberg JP, Servick S, Kaufmann G et al: Elimination of antigen-presenting cells and 
autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 2007, 
26(5):629-641. 
116. Mathis D, Vence L, Benoist C: beta-Cell death during progression to diabetes. Nature 2001, 
414(6865):792-798. 
117. La Torre D, Lernmark A: Immunology of beta-cell destruction. Adv Exp Med Biol 2010, 654:537-
583. 
118. Wang Y, Pontesilli O, Gill RG, La Rosa FG, Lafferty KJ: The role of CD4+ and CD8+ T cells in the 
destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci U S A 1991, 
88(2):527-531. 
119. Nagata M, Santamaria P, Kawamura T, Utsugi T, Yoon JW: Evidence for the role of CD8+ 
cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J 





120. Christianson SW, Shultz LD, Leiter EH: Adoptive transfer of diabetes into immunodeficient 
NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus 
prediabetic NOD.NON-Thy-1a donors. Diabetes 1993, 42(1):44-55. 
121. Haskins K, McDuffie M: Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T 
cell clone. Science 1990, 249(4975):1433-1436. 
122. Charre S, Rosmalen JG, Pelegri C, Alves V, Leenen PJ, Drexhage HA, Homo-Delarche F: 
Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese 
diabetic (NOD) mice during the early neonatal period. Histol Histopathol 2002, 17(2):393-401. 
123. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW: The role of macrophages in T cell-
mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999, 189(2):347-358. 
124. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA: Potential role of resident islet 
macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998, 160(6):2684-
2691. 
125. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA: IL-1 produced and 
released endogenously within human islets inhibits beta cell function. J Clin Invest 1998, 
102(3):516-526. 
126. Scarim AL, Arnush M, Hill JR, Marshall CA, Baldwin A, McDaniel ML, Corbett JA: Evidence for the 
presence of type I IL-1 receptors on beta-cells of islets of Langerhans. Biochim Biophys Acta 
1997, 1361(3):313-320. 
127. Corbett JA, McDaniel ML: Intraislet release of interleukin 1 inhibits beta cell function by 
inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 1995, 181(2):559-
568. 
128. Rabinovitch A, Suarez-Pinzon WL: Cytokines and their roles in pancreatic islet beta-cell 
destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998, 55(8):1139-
1149. 
129. Ankarcrona M, Dypbukt JM, Brune B, Nicotera P: Interleukin-1 beta-induced nitric oxide 
production activates apoptosis in pancreatic RINm5F cells. Exp Cell Res 1994, 213(1):172-177. 
130. Signore A, Pozzilli P, Gale EA, Andreani D, Beverley PC: The natural history of lymphocyte 
subsets infiltrating the pancreas of NOD mice. Diabetologia 1989, 32(5):282-289. 
131. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M: Nitric oxide 
primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes 
mellitus. J Exp Med 1997, 186(8):1193-1200. 
132. Pakala SV, Chivetta M, Kelly CB, Katz JD: In autoimmune diabetes the transition from benign to 
pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 
1999, 189(7):1053-1062. 
133. Stephens LA, Thomas HE, Ming L, Grell M, Darwiche R, Volodin L, Kay TW: Tumor necrosis 
factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic 
beta cells. Endocrinology 1999, 140(7):3219-3227. 
134. Nolsoe RL, Kristiansen OP, Sangthongpitag K, Larsen ZM, Johannesen J, Karlsen AE, Pociot F, 
Nerup J, Verge CF, Mandrup-Poulsen T: Complete molecular scanning of the human Fas gene: 
mutational analysis and linkage studies in families with type I diabetes mellitus. The Danish 
Study Group of Diabetes in Childhood and The Danish IDDM Epidemiology and Genetics 
Group. Diabetologia 2000, 43(6):800-808. 
135. Eckenrode S, Marron MP, Nicholls R, Yang MC, Yang JJ, Guida Fonseca LC, She JX: Fine-mapping 
of the type 1 diabetes locus (IDDM4) on chromosome 11q and evaluation of two candidate 






136. Sangthongpitag K, Moore KR, Lapsys NM, Bao F, Babu SR, Fain PR, Verge CF: No evidence for 
linkage of a novel CA repeat polymorphism for apoptosis antigen 1 (APO-1 or fas) with type I 
diabetes in a Caucasian population. Hum Hered 1998, 48(6):343-345. 
137. Allison J, Strasser A: Mechanisms of beta cell death in diabetes: a minor role for CD95. Proc 
Natl Acad Sci U S A 1998, 95(23):13818-13822. 
138. Su X, Hu Q, Kristan JM, Costa C, Shen Y, Gero D, Matis LA, Wang Y: Significant role for Fas in the 
pathogenesis of autoimmune diabetes. J Immunol 2000, 164(5):2523-2532. 
139. Savinov AY, Tcherepanov A, Green EA, Flavell RA, Chervonsky AV: Contribution of Fas to 
diabetes development. Proc Natl Acad Sci U S A 2003, 100(2):628-632. 
140. Kim S, Kim KA, Hwang DY, Lee TH, Kayagaki N, Yagita H, Lee MS: Inhibition of autoimmune 
diabetes by Fas ligand: the paradox is solved. J Immunol 2000, 164(6):2931-2936. 
141. Mohamood AS, Guler ML, Xiao Z, Zheng D, Hess A, Wang Y, Yagita H, Schneck JP, Hamad AR: 
Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL 
mutation are differentially regulated and can be uncoupled pharmacologically. Am J Pathol 
2007, 171(1):97-106. 
142. Xiao Z, Mohamood AS, Uddin S, Gutfreund R, Nakata C, Marshall A, Kimura H, Caturegli P, 
Womer KL, Huang Y et al: Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-
10 against insulitis development. Am J Pathol 2011, 179(2):725-732. 
143. Balasa B, Van Gunst K, Jung N, Balakrishna D, Santamaria P, Hanafusa T, Itoh N, Sarvetnick N: 
Islet-specific expression of IL-10 promotes diabetes in nonobese diabetic mice independent of 
Fas, perforin, TNF receptor-1, and TNF receptor-2 molecules. J Immunol 2000, 165(5):2841-
2849. 
144. Wen L, Green EA, Stratmann T, Panosa A, Gomis R, Eynon EE, Flavell RA, Mezquita JA, Mora C: In 
vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of 
IL-1 and IL-18. Eur J Immunol 2011, 41(5):1344-1351. 
145. Amrani A, Verdaguer J, Thiessen S, Bou S, Santamaria P: IL-1alpha, IL-1beta, and IFN-gamma 
mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J Clin 
Invest 2000, 105(4):459-468. 
146. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD: 
Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets 
prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. 
Diabetes 1999, 48(9):1730-1736. 
147. Angstetra E, Graham KL, Emmett S, Dudek NL, Darwiche R, Ayala-Perez R, Allison J, Santamaria 
P, Kay TW, Thomas HE: In vivo effects of cytokines on pancreatic beta-cells in models of type I 
diabetes dependent on CD4(+) T lymphocytes. Immunol Cell Biol 2009, 87(2):178-185. 
148. Allison J, Thomas HE, Catterall T, Kay TW, Strasser A: Transgenic expression of dominant-
negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced 
apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. J Immunol 2005, 
175(1):293-301. 
149. Mollah ZU, Wali J, McKenzie MD, Krishnamurthy B, Graham KL, Fynch S, Szanyi J, Santamaria P, 
Brodnicki T, Allison J et al: The pro-apoptotic BH3-only protein Bid is dispensable for 
development of insulitis and diabetes in the non-obese diabetic mouse. Apoptosis 2011, 
16(8):822-830. 
150. Schumann DM, Maedler K, Franklin I, Konrad D, Storling J, Boni-Schnetzler M, Gjinovci A, Kurrer 
MO, Gauthier BR, Bosco D et al: The Fas pathway is involved in pancreatic beta cell secretory 





151. Nakayama M, Nagata M, Yasuda H, Arisawa K, Kotani R, Yamada K, Chowdhury SA, Chakrabarty 
S, Jin ZZ, Yagita H et al: Fas/Fas ligand interactions play an essential role in the initiation of 
murine autoimmune diabetes. Diabetes 2002, 51(5):1391-1397. 
152. Kim YH, Kim S, Kim KA, Yagita H, Kayagaki N, Kim KW, Lee MS: Apoptosis of pancreatic beta-cells 
detected in accelerated diabetes of NOD mice: no role of Fas-Fas ligand interaction in 
autoimmune diabetes. Eur J Immunol 1999, 29(2):455-465. 
153. Apostolou I, Hao Z, Rajewsky K, von Boehmer H: Effective destruction of Fas-deficient insulin-
producing beta cells in type 1 diabetes. J Exp Med 2003, 198(7):1103-1106. 
154. Vence L, Benoist C, Mathis D: Fas deficiency prevents type 1 diabetes by inducing 
hyporesponsiveness in islet beta-cell-reactive T-cells. Diabetes 2004, 53(11):2797-2803. 
155. Choi D, Radziszewska A, Schroer SA, Liadis N, Liu Y, Zhang Y, Lam PP, Sheu L, Hao Z, Gaisano HY 
et al: Deletion of Fas in the pancreatic beta-cells leads to enhanced insulin secretion. Am J 
Physiol Endocrinol Metab 2009, 297(6):E1304-1312. 
156. Jin Y, Qu A, Wang GM, Hao J, Gao X, Xie S: Simultaneous stimulation of Fas-mediated apoptosis 
and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-
dose streptozotocin. Gene Ther 2004, 11(12):982-991. 
157. Chong MM, Chen Y, Darwiche R, Dudek NL, Irawaty W, Santamaria P, Allison J, Kay TW, Thomas 
HE: Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from 
CD8+ T cell-mediated autoimmune destruction. J Immunol 2004, 172(9):5714-5721. 
158. Suarez-Pinzon WL, Power RF, Rabinovitch A: Fas ligand-mediated mechanisms are involved in 
autoimmune destruction of islet beta cells in non-obese diabetic mice. Diabetologia 2000, 
43(9):1149-1156. 
159. Vijayan S, Zhou P, Rajapaksha TW, Alegre ML, Peter ME: Transplanted islets from lpr mice are 
resistant to autoimmune destruction in a model of streptozotocin-induced type I diabetes. 
Apoptosis 2005, 10(4):725-730. 
160. Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H: A novel multimeric form of FasL 
modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive 
transfer model. Mol Immunol 2007, 44(11):2884-2892. 
161. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA: Comparing the relative role of 
perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-
dependent diabetes mellitus. J Immunol 1999, 163(8):4335-4341. 
162. McKenzie MD, Dudek NL, Mariana L, Chong MM, Trapani JA, Kay TW, Thomas HE: Perforin and 
Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol 
2006, 18(6):837-846. 
163. Dudek NL, Thomas HE, Mariana L, Sutherland RM, Allison J, Estella E, Angstetra E, Trapani JA, 
Santamaria P, Lew AM et al: Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice 
destroy beta-cells via the perforin and Fas pathways. Diabetes 2006, 55(9):2412-2418. 
164. Anderson MS, Bluestone JA: The NOD mouse: a model of immune dysregulation. Annu Rev 
Immunol 2005, 23:447-485. 
165. Mathews CE: Utility of murine models for the study of spontaneous autoimmune type 1 
diabetes. Pediatr Diabetes 2005, 6(3):165-177. 
166. Ingelsson E, Saldeen J, Welsh N: Islet expression of perforin, Fas/Apo-1 and interleukin-1 
converting enzyme (ICE) in non-obese diabetic (NOD) mice. Immunol Lett 1998, 63(3):125-129. 
167. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL: Radiation and stress-induced 
apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci U S A 1997, 94(11):5750-
5755. 
168. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 





169. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD: AAV8-mediated gene transfer of 
interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 
2008, 16(8):1409-1416. 
170. Araki R, Fujimori A, Hamatani K, Mita K, Saito T, Mori M, Fukumura R, Morimyo M, Muto M, Itoh 
M et al: Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic 
subunit of severe combined immune deficiency mice. Proc Natl Acad Sci U S A 1997, 
94(6):2438-2443. 
171. Moriwaki M, Itoh N, Miyagawa J, Yamamoto K, Imagawa A, Yamagata K, Iwahashi H, Nakajima H, 
Namba M, Nagata S et al: Fas and Fas ligand expression in inflamed islets in pancreas sections 
of patients with recent-onset Type I diabetes mellitus. Diabetologia 1999, 42(11):1332-1340. 
172. Sayama K, Imagawa A, Okita K, Uno S, Moriwaki M, Kozawa J, Iwahashi H, Yamagata K, Tamura 
S, Matsuzawa Y et al: Pancreatic beta and alpha cells are both decreased in patients with 
fulminant type 1 diabetes: a morphometrical assessment. Diabetologia 2005, 48(8):1560-1564. 
173. Augstein P, Wachlin G, Berg S, Bahr J, Salzsieder C, Hehmke B, Heinke P, Salzsieder E: Surface 
and intracellular Fas expression associated with cytokine-induced apoptosis in rodent islet and 
insulinoma cells. J Mol Endocrinol 2003, 30(2):163-171. 
174. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin 
KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of 
the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic 
cells. Lab Invest 1993, 69(4):415-429. 
175. Loweth AC, Williams GT, James RF, Scarpello JH, Morgan NG: Human islets of Langerhans 
express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. 
Diabetes 1998, 47(5):727-732. 
176. Cao JY, Wang H: Role of Fas-FasL in insulitis in nonobese diabetic mouse. Chin Med J (Engl) 
2004, 117(4):615-617. 
177. Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A: Beta-cell 
destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and 
proinflammatory cytokine expression in islets. Diabetes 1999, 48(1):21-28. 
178. Darwiche R, Chong MM, Santamaria P, Thomas HE, Kay TW: Fas is detectable on beta cells in 
accelerated, but not spontaneous, diabetes in nonobese diabetic mice. J Immunol 2003, 
170(12):6292-6297. 
179. Thomas HE, Darwiche R, Corbett JA, Kay TW: Evidence that beta cell death in the nonobese 
diabetic mouse is Fas independent. J Immunol 1999, 163(3):1562-1569. 
180. Reddy S, Ross JM: Fas and Fas ligand immunoexpression in pancreatic islets of NOD mice 
during spontaneous and cyclophosphamide-accelerated diabetes. Ann N Y Acad Sci 2003, 
1005:166-169. 
181. Signore A, Annovazzi A, Procaccini E, Beales PE, Spencer J, Testi R, Ruberti G: CD95 and CD95-
ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. Diabetologia 1997, 
40(12):1476-1479. 
182. Dharnidharka VR, Van Patten Y, Bahjat FR, Clare-Salzler M: Fas stimulation results in selective 
islet infiltrate apoptosis in situ and reversal of diabetes. Ann N Y Acad Sci 2002, 958:160-162. 
183. Sainio-Pollanen S, Liukas A, Pollanen P, Simell O: The role of CD8+ cells, cell degeneration, and 
Fas ligand in insulitis after intraperitoneal transfer of NOD splenocytes. Pancreas 1999, 
18(3):282-293. 
184. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY: 
Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. 





185. Lee MS, Kim S, Chung JH, Lee MK, Kim KW: Fas is expressed in murine pancreatic islet cells and 
an insulinoma cell line but does not mediate their apoptosis in vitro. Autoimmunity 1999, 
29(3):189-199. 
186. Smith D, Sieg S, Kaplan D: Technical note: Aberrant detection of cell surface Fas ligand with 
anti-peptide antibodies. J Immunol 1998, 160(9):4159-4160. 
187. Zumsteg U, Frigerio S, Hollander GA: Nitric oxide production and Fas surface expression 
mediate two independent pathways of cytokine-induced murine beta-cell damage. Diabetes 
2000, 49(1):39-47. 
188. Bai-Feng L, Yong-Feng L, Ying C: Silencing inducible nitric oxide synthase protects rat pancreatic 
islet. Diabetes Res Clin Pract 2010, 89(3):268-275. 
189. Wachlin G, Augstein P, Schroder D, Kuttler B, Kloting I, Heinke P, Schmidt S: IL-1beta, IFN-
gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune 
destruction. J Autoimmun 2003, 20(4):303-312. 
190. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K: Mouse islet cell lysis 
mediated by interleukin-1-induced Fas. Diabetologia 1996, 39(11):1306-1312. 
191. Augstein P, Dunger A, Salzsieder C, Heinke P, Kubernath R, Bahr J, Fischer U, Rettig R, Salzsieder 
E: Cell surface trafficking of Fas in NIT-1 cells and dissection of surface and total Fas 
expression. Biochem Biophys Res Commun 2002, 290(1):443-451. 
192. Maedler K, Schumann DM, Schulthess F, Oberholzer J, Bosco D, Berney T, Donath MY: Aging 
correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to 
apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. Diabetes 2006, 
55(9):2455-2462. 
193. Mellado-Gil JM, Aguilar-Diosdado M: High glucose potentiates cytokine- and streptozotocin-
induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol 2004, 
183(1):155-162. 
194. Loweth AC, Watts K, McBain SC, Williams GT, Scarpello JH, Morgan NG: Dissociation between 
Fas expression and induction of apoptosis in human islets of Langerhans. Diabetes Obes Metab 
2000, 2(1):57-60. 
195. Mannick JB, Miao XQ, Stamler JS: Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 1997, 
272(39):24125-24128. 
196. Lin B, Zhang ZL, Yu LY, Guo LH: CMV-hFasL transgenic mice are sensitive to low doses of 
streptozotocin-induced type I diabetes mellitus. Acta Pharmacol Sin 2003, 24(12):1199-1204. 
197. Augstein P, Heinke P, Schober C, Salzsieder E: Impact of Cytokine- and FasL-induced Apoptosis 
in the β-Cell Line NIT-1. Horm Metab Res 2009, 41(03):207,212. 
198. Burkhardt BR, Lyle R, Qian K, Arnold AS, Cheng H, Atkinson MA, Zhang YC: Efficient delivery of 
siRNA into cytokine-stimulated insulinoma cells silences Fas expression and inhibits Fas-
mediated apoptosis. FEBS Lett 2006, 580(2):553-560. 
199. Augstein P, Heinke P, Salzsieder E, Berg S, Rettig R, Salzsieder C, Harrison LC: Fas ligand down-
regulates cytokine-induced Fas receptor expression on insulinoma (NIT-1), but not islet cells, 
from autoimmune nonobese diabetic mice. Endocrinology 2004, 145(6):2747-2752. 
200. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL: Cytokines induce apoptosis in 
beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). 
Diabetes 2000, 49(7):1116-1122. 
201. Kurrer MO, Pakala SV, Hanson HL, Katz JD: Beta cell apoptosis in T cell-mediated autoimmune 
diabetes. Proc Natl Acad Sci U S A 1997, 94(1):213-218. 
202. Herrera PL, Harlan DM, Vassalli P: A mouse CD8 T cell-mediated acute autoimmune diabetes 
independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc 





203. Lawrence CP, Chow SC: FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent 
necrosis during activation-induced cell death. FEBS Lett 2005, 579(28):6465-6472. 
204. Gorak-Stolinska P, Truman JP, Kemeny DM, Noble A: Activation-induced cell death of human T-
cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol 
2001, 70(5):756-766. 
205. Kagi D, Odermatt B, Ohashi PS, Zinkernagel RM, Hengartner H: Development of insulitis without 
diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med 1996, 
183(5):2143-2152. 
206. Amrani A, Verdaguer J, Anderson B, Utsugi T, Bou S, Santamaria P: Perforin-independent beta-
cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J 
Clin Invest 1999, 103(8):1201-1209. 
207. Qin H, Trudeau JD, Reid GS, Lee IF, Dutz JP, Santamaria P, Verchere CB, Tan R: Progression of 
spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used 
by autoreactive CTL. Int Immunol 2004, 16(11):1657-1662. 
208. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of a DNA polymerase beta gene 
segment in T cells using cell type-specific gene targeting. Science 1994, 265(5168):103-106. 
209. Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev 
Immunol 2002, 2(6):410-416. 
210. Lightfoot YL, Chen J, Mathews CE: Role of the Mitochondria in Immune-Mediated Apoptotic 
Death of the Human Pancreatic beta Cell Line betaLox5. PLoS One 2011, 6(6):e20617. 
211. Darville MI, Eizirik DL: Cytokine induction of Fas gene expression in insulin-producing cells 
requires the transcription factors NF-kappaB and C/EBP. Diabetes 2001, 50(8):1741-1748. 
212. Hu P, Wang G, Zhu X, Yang J, Zhu H, Xu Z, Liao W, Liu X, Xu F, Yin J et al: FADDdel-GFP modified 
mouse insulinoma cells counteract the cytotoxicity of reactive T cells. Cell Mol Immunol 2004, 
1(5):383-386. 
213. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato 
A, Spinas GA et al: FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells 
from apoptosis to cell replication. Proc Natl Acad Sci U S A 2002, 99(12):8236-8241. 
214. Yamada K, Ichikawa F, Ishiyama-Shigemoto S, Yuan X, Nonaka K: Essential role of caspase-3 in 
apoptosis of mouse beta-cells transfected with human Fas. Diabetes 1999, 48(3):478-483. 
215. Augstein P, Bahr J, Wachlin G, Heinke P, Berg S, Salzsieder E, Harrison LC: Cytokines activate 
caspase-3 in insulinoma cells of diabetes-prone NOD mice directly and via upregulation of Fas. 
J Autoimmun 2004, 23(4):301-309. 
216. Desbarats J, Newell MK: Fas engagement accelerates liver regeneration after partial 
hepatectomy. Nat Med 2000, 6(8):920-923. 
217. Vaux DL: Immunology. Ways around rejection. Nature 1995, 377(6550):576-577. 
218. Silva DG, Petrovsky N, Socha L, Slattery R, Gatenby P, Charlton B: Mechanisms of accelerated 
immune-mediated diabetes resulting from islet beta cell expression of a Fas ligand transgene. 
J Immunol 2003, 170(10):4996-5002. 
219. Petrovsky N, Silva D, Socha L, Slattery R, Charlton B: The role of Fas ligand in beta cell 
destruction in autoimmune diabetes of NOD mice. Ann N Y Acad Sci 2002, 958:204-208. 
220. Allison J, Georgiou HM, Strasser A, Vaux DL: Transgenic expression of CD95 ligand on islet beta 
cells induces a granulocytic infiltration but does not confer immune privilege upon islet 
allografts. Proc Natl Acad Sci U S A 1997, 94(8):3943-3947. 
221. Christen U, Darwiche R, Thomas HE, Wolfe T, Rodrigo E, Chervonsky A, Flavell RA, von Herrath 
MG: Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells. 





222. Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL, Dichek DA, Baekkeskov S, Stock 
PG: A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet 
transplants. Transplantation 2000, 69(9):1813-1817. 
223. Silva DG, Socha L, Charlton B, Cowden W, Petrovsky N: Autoimmune diabetes in the NOD 
mouse: an essential role of Fas-FasL signaling in beta cell apoptosis. Ann N Y Acad Sci 2003, 
1005:161-165. 
224. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S: Fas ligand 
expression in islets of Langerhans does not confer immune privilege and instead targets them 
for rapid destruction. Nat Med 1997, 3(7):738-743. 
225. Takeda Y, Gotoh M, Dono K, Nishihara M, Grochowiecki T, Kimura F, Yoshida T, Ohta Y, Ota H, 
Ohzato H et al: Protection of islet allografts transplanted together with Fas ligand expressing 
testicular allografts. Diabetologia 1998, 41(3):315-321. 
226. Lau HT, Yu M, Fontana A, Stoeckert CJ, Jr.: Prevention of islet allograft rejection with 
engineered myoblasts expressing FasL in mice. Science 1996, 273(5271):109-112. 
227. Jeong JH, Kim SH, Lee M, Kim WJ, Park TG, Ko KS, Kim SW: Non-viral systemic delivery of Fas 
siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. J Control Release 2010, 
143(1):88-94. 
228. Mahiou J, Walter U, Lepault F, Godeau F, Bach JF, Chatenoud L: In vivo blockade of the Fas-Fas 
ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J Autoimmun 2001, 
16(4):431-440. 
229. Sainio-Pollanen S, Erkkila S, Alanko S, Hanninen A, Pollanen P, Simell O: The role of Fas ligand in 
the development of insulitis in nonobese diabetic mice. Pancreas 1998, 16(2):154-159. 
230. Giordano C, De Maria R, Stassi G, Todaro M, Richiusa P, Giordano M, Testi R, Galluzzo A: 
Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in 
IDDM. Diabetologia 1995, 38(12):1449-1454. 
231. Decallonne B, van Etten E, Giulietti A, Casteels K, Overbergh L, Bouillon R, Mathieu C: Defect in 
activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003, 
20(3):219-226. 
232. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, 
Mathis D, Rossini AA, Campbell SE et al: A comprehensive review of interventions in the NOD 

























Classification of Literature Review Style 
 
This literature review is categorized as a narrative review (vs. systematic) for the following reasons:
 1. Critically analyzes and discusses the current state of a specific science topic. 
 2. Does not use a methodological approach in which readers could reproduce the data 
reported solely by reading the review document.  
3. Narrative approach summarizes relevant primary literature. See Figure 3 for method of article 
selection. 
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Table 3. Compilation of Fas β-cell death-relevant search terms 
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